{"custom_id": "R00001", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nVomiting in acute theophylline toxicity has assumed increased clinical importance since the introduction of multiple dose activated charcoal therapy. We performed a prospective study of 26 patients with acute overdose of sustained release theophylline to characterize vomiting, and its possible interference with the acceptance of activated charcoal. Twenty five of 26 patients vomited. The duration of vomiting correlated with both peak serum theophylline concentrations (p less than 0.001) and the duration of theophylline toxicity (p less than 0.001). Vomiting extended over 63% of the drug's absorptive phase (the time interval between ingestion and the peak level) and 49% of the elimination phase (the time interval between the peak level and decrease of theophylline level to less than 20 mcg/ml). Patients with peak serum theophylline concentrations less than 70 mcg/ml were able to accept larger amounts of activated charcoal than patients with serum theophylline concentrations greater than 70 mcg/ml (113 +/- 15 gms vs. 57 +/- 24 gms, p less than 0.05). Vomiting in acute sustained release theophylline toxicity is protracted, and limits the use of activated charcoal especially in patients with severe acute theophylline poisoning.\n"}], "temperature": 0.0}}
{"custom_id": "R00002", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nPlant-derived medicines have a long history of use for the prevention and treatment of human disease. Today, many pharmaceuticals currently approved by the Food and Drug Administration (FDA) have origins to plant sources. A major role for plant-derived compounds based on the reported immunomodulatory effects has emerged in recent times and has led to the rigorous scientific examination to determine efficacy and safety. The discovery of novel plant compounds with immune system modulating activities has become an increasingly important area of research, particularly in the search for new-generation vaccine adjuvants. This review discusses the important role of plant-derived medicines as immunomodulators and provides evidence in support of the continued investigation of this new class of drugs for the maintenance of human health. The identification and characterization of plant compounds that augment new or existing vaccines, and in particular mucosally administered vaccines, will be of significant interest to vaccinologists and immunologists. (c) 2010 Elsevier B.V. All rights reserved.\n"}], "temperature": 0.0}}
{"custom_id": "R00003", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nAbstract Introduction: Gastric lavage involves the removal of potentially toxic substances from the stomach before they are systemically absorbed. Despite its widespread use, gastric lavage still lacks consensus among the clinical and scientific community. Objective: To identify and map the available scientific evidence regarding gastric lavage in individuals suffering from acute poisoning. Methods: The review followed the JBI methodology for scoping reviews and was conducted according to the PRISMA-ScR checklist. We considered studies involving adult individuals, victims of poisoning, undergoing gastric lavage in intra or extra-hospital settings. Studies in English, French, Spanish, and Portuguese were included. Study selection was performed by two independent reviewers, with a third reviewer in case of disagreement. Results: After the selection process, 10 articles were included. Gastric lavage is performed by instilling 300mL of saline/water through a nasogastric catheter with subsequent removal of all gastric contents. Gastric lavage should be performed within the first hour after poisoning; beyond this time limit, it is not beneficial, except in cases of tricyclic antidepressant poisoning. Other decontamination methods, such as activated charcoal (greater efficacy) and ipecac syrup (similar efficacy), exist. Conclusion: Gastric lavage has been shown to be a procedure that should be applied in very specific circumstances and should take into account aspects such as the time of contamination, the person and their clinical condition. Other procedures should also be considered, which may be more effective and less risky for the poisoned person.\n"}], "temperature": 0.0}}
{"custom_id": "R00004", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nSimple Summary We attempted to identify target proteins and compounds that can be used to overcome EGFR-TKI resistance in NSCLC. To accomplish this, we generated EGFR inhibitor erlotinib-resistant HCC827-ErlR cells and obtained a list of differentially expressed genes. Then, we performed connectivity map analysis and identified heat shock factor 1 (HSF1) as a potential target protein to overcome erlotinib resistance. Using specific HSF1 shRNAs and KRIBB11 (N-2-(1H-Indazol-5-yl)-N-6-methyl-3-nitropyridine-2,6-diamine), we proved the effectiveness of HSF1 inhibition for overcoming erlotinib resistance in vitro. In addition, we proved the efficacy of emetine in inhibiting HSF1 activity and the tumor growth of erlotinib-resistant PC9-ErlR cells in a mouse model. Although EGFR-TKI treatment of NSCLC (non-small-cell lung cancer) patients often achieves profound initial responses, the efficacy is transient due to acquired resistance. Multiple receptor tyrosine kinase (RTK) pathways contribute to the resistance of NSCLC to first- and third-generation EGFR-TKIs, such as erlotinib and osimertinib. To identify potential targets for overcoming EGFR-TKI resistance, we performed a gene expression signature-based strategy using connectivity map (CMap) analysis. We generated erlotinib-resistant HCC827-ErlR cells, which showed resistance to erlotinib, gefitinib, osimertinib, and doxorubicin. A list of differentially expressed genes (DEGs) in HCC827-ErlR cells was generated and queried using CMap analysis. Analysis of the top 4 compounds from the CMap list suggested HSF1 as a potential target to overcome EGFR-TKI resistance. HSF1 inhibition by using HSF1 shRNAs or KRIBB11 decreased the expression of HSF1 downstream proteins, such as HSP70 and HSP27, and also decreased the expression of HSP90/HSP70/BAG3 client proteins, such as BCL2, MCL1, EGFR, MET, and AXL, causing apoptosis of EGFR-TKI-resistant cancer cells. Finally, we demonstrated the efficacy of the HSF1 inhibitor on PC9-ErlR cells expressing mutant EGFR (T790M) in vivo. Collectively, these findings support a targetable HSF1-(HSP90/HSP70/BAG3)-(BCL2/MCL1/EGFR/MET/AXL) pathway to overcome multiple mechanisms of EGFR-TKI resistance.\n"}], "temperature": 0.0}}
{"custom_id": "R00005", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\n1. Selective 5-HT3-receptor antagonists are highly effective in preventing nausea and vomiting associated with chemotherapy, radiotherapy and surgery. Their pharmacological activity may be determined in vitro and in animal models of emesis. However, these methods may not give an accurate indication of the antiemetic dose range of 5-HT3-receptor antagonists in patients. Two volunteer models have been used to predict more accurately clinically effective antiemetic doses of 5-HT3-receptor antagonists. 2. The flare response to intradermal 5-HT is thought to be mediated by excitation of 5-HT3-receptors on cutaneous afferents, with release of substance P and subsequent vasodilation. Antagonism of the flare response appears to provide an indication of the effective antiemetic dose of 5-HT3-receptor antagonists but data on duration of action are conflicting. 3. Ipecacuanha-induced emesis is thought to be mediated through both peripheral and central 5-HT3-receptors. Antagonism of this response has demonstrated a close correlation with clinically effective antiemetic doses of the specific 5-HT3-receptor antagonist, ondansetron, and has the advantage of being more conceptually relevant than the flare model. 4. Further work, with newer 5-HT3-receptor antagonists, will clarify the role of these models as predictive of the use of these drugs in clinical practice.\n"}], "temperature": 0.0}}
{"custom_id": "R00006", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nWhole bowel irrigation with polyethylene glycol electrolyte lavage solution has been recommended as an adjunct to traditional overdose management. Although combined activated charcoal and whole bowel irrigation could enhance the efficacy of both modalities, this improvement remains largely speculative. An in vitro experiment was designed to determine whether polyethylene glycol electrolyte lavage solution alters the adsorption of theophylline to activated charcoal. Theophylline was agitated with activated charcoal in either water or polyethylene glycol electrolyte lavage solution, at each of three activated charcoal:theophylline ratios; 1:1, 3:1, and 10:1. The concentration in the supernatant was determined by high pressure liquid chromatography, and the maximal adsorptive capacity of activated charcoal for theophylline was calculated from the Langmuir equation. The percent of theophylline adsorbed by activated charcoal in water was 16 +/- 4%, 67 +/- 5%, and 97 +/- 3% for the 1:1, 3:1, and 10:1 ratios, respectively. This was decreased to 17 +/- 5%, 37 +/- 3%, and 62 +/- 2% when polyethylene glycol electrolyte lavage solution was added. A statistical difference (p less than 0.05) occurred at the 3:1 and 10:1 activated charcoal:theophylline ratios. Similarly the maximal adsorptive capacity was decreased 23% from 264 mg/g to 203 mg/g when polyethylene glycol electrolyte lavage solution was added to activated charcoal prior to theophylline. Polyethylene glycol electrolyte lavage solution significantly decreases adsorption of theophylline to activated charcoal in vitro. In vivo studies are required to confirm these findings. If activated charcoal is to be used clinically for theophylline toxicity, the authors suggest the possibility of larger quantities of activated charcoal, and administering activated charcoal in a slurry of water before the initiation of whole bowel irrigation.\n"}], "temperature": 0.0}}
{"custom_id": "R00007", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nBackgroundIn industrialised countries injuries (including burns, poisoning or drowning) are the leading cause of childhood death and steep social gradients exist in child injury mortality and morbidity. The majority of injuries in pre-school children occur at home but there is little meta-analytic evidence that child home safety interventions reduce injury rates or improve a range of safety practices, and little evidence on their effect by social group.ObjectivesWe evaluated the effectiveness of home safety education, with or without the provision of low cost, discounted or free equipment (hereafter referred to as home safety interventions), in reducing child injury rates or increasing home safety practices and whether the effect varied by social group.Search methodsWe searched the Cochrane Central Register of Controlled Trials (CENTRAL) (2009, Issue 2) in The Cochrane Library, MEDLINE (Ovid), EMBASE (Ovid), PsycINFO (Ovid), ISI Web of Science: Science Citation Index Expanded (SCI-EXPANDED), ISI Web of Science: Social Sciences Citation Index (SSCI), ISI Web of Science: Conference Proceedings Citation Index-Science (CPCI-S), CINAHL (EBSCO) and DARE (2009, Issue 2) in The Cochrane Library. We also searched websites and conference proceedings and searched the bibliographies of relevant studies and previously published reviews. We contacted authors of included studies as well as relevant organisations. The most recent search for trials was May 2009.Selection criteriaRandomised controlled trials (RCTs), non-randomised controlled trials and controlled before and after (CBA) studies where home safety education with or without the provision of safety equipment was provided to those aged 19 years and under, and which reported injury, safety practices or possession of safety equipment.Data collection and analysisTwo authors independently assessed study quality and extracted data. We attempted to obtain individual participant level data (IPD) for all included studies and summary data and IPD were simultaneously combined in meta-regressions by social and demographic variables. Pooled incidence rate ratios (IRR) were calculated for injuries which occurred during the studies, and pooled odds ratios were calculated for the uptake of safety equipment or safety practices, with 95% confidence intervals.Main resultsNinety-eight studies, involving 2,605,044 people, are included in this review. Fifty-four studies involving 812,705 people were comparable enough to be included in at least one meta-analysis. Thirty-five (65%) studies were RCTs. Nineteen (35%) of the studies included in the meta-analysis provided IPD.There was a lack of evidence that home safety interventions reduced rates of thermal injuries or poisoning. There was some evidence that interventions may reduce injury rates after adjusting CBA studies for baseline injury rates (IRR 0.89, 95% CI 0.78 to 1.01). Greater reductions in injury rates were found for interventions delivered in the home (IRR 0.75, 95% CI 0.62 to 0.91), and for those interventions not providing safety equipment (IRR 0.78, 95% CI 0.66 to 0.92).Home safety interventions were effective in increasing the proportion of families with safe hot tap water temperatures (OR 1.41, 95% CI 1.07 to 1.86), functional smoke alarms (OR 1.81, 95% CI 1.30 to 2.52), a fire escape plan (OR 2.01, 95% CI 1.45 to 2.77), storing medicines (OR 1.53, 95% CI 1.27 to 1.84) and cleaning products (OR 1.55, 95% CI 1.22 to 1.96) out of reach, having syrup of ipecac (OR 3.34, 95% CI 1.50 to 7.44) or poison control centre numbers accessible (OR 3.30, 95% CI 1.70 to 6.39), having fitted stair gates (OR 1.61, 95% CI 1.19 to 2.17), and having socket covers on unused sockets (OR 2.69, 95% CI 1.46 to 4.96).Interventions providing free, low cost or discounted safety equipment appeared to be more effective in improving some safety practices than those interventions not doing so. There was no consistent evidence that interventions were less effective in families whose children were at greater risk of injury.Authors' conclusionsHome safety interventions most commonly provided as one-to-one, face-to-face education, especially with the provision of safety equipment, are effective in increasing a range of safety practices. There is some evidence that such interventions may reduce injury rates, particularly where interventions are provided at home. Conflicting findings regarding interventions providing safety equipment on safety practices and injury outcomes are likely to be explained by two large studies; one clinic-based study provided equipment but did not reduce injury rates and one school-based study did not provide equipment but did demonstrate a significant reduction in injury rates. There was no consistent evidence that home safety education, with or without the provision of safety equipment, was less effective in those participants at greater risk of injury. Further studies are still required to confirm these findings with respect to injury rates.\n"}], "temperature": 0.0}}
{"custom_id": "R00008", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nBACKGROUND: In industrialised countries injuries (including burns, poisoning or drowning) are the leading cause of childhood death and steep social gradients exist in child injury mortality and morbidity. The majority of injuries in pre-school children occur at home but there is little meta-analytic evidence that child home safety interventions reduce injury rates or improve a range of safety practices, and little evidence on their effect by social group.OBJECTIVES: We evaluated the effectiveness of home safety education, with or without the provision of low cost, discounted or free equipment (hereafter referred to as home safety interventions), in reducing child injury rates or increasing home safety practices and whether the effect varied by social group.SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (2009, Issue 2) in The Cochrane Library, MEDLINE (Ovid), EMBASE (Ovid), PsycINFO (Ovid), ISI Web of Science: Science Citation Index Expanded (SCI-EXPANDED), ISI Web of Science: Social Sciences Citation Index (SSCI), ISI Web of Science: Conference Proceedings Citation Index- Science (CPCI-S), CINAHL (EBSCO) and DARE (2009, Issue 2) in The Cochrane Library. We also searched websites and conference proceedings and searched the bibliographies of relevant studies and previously published reviews. We contacted authors of included studies as well as relevant organisations. The most recent search for trials was May 2009.SELECTION CRITERIA: Randomised controlled trials (RCTs), non-randomised controlled trials and controlled before and after (CBA) studies where home safety education with or without the provision of safety equipment was provided to those aged 19 years and under, and which reported injury, safety practices or possession of safety equipment.DATA COLLECTION AND ANALYSIS: Two authors independently assessed study quality and extracted data. We attempted to obtain individual participant level data (IPD) for all included studies and summary data and IPD were simultaneously combined in meta-regressions by social and demographic variables. Pooled incidence rate ratios (IRR) were calculated for injuries which occurred during the studies, and pooled odds ratios were calculated for the uptake of safety equipment or safety practices, with 95% confidence intervals.MAIN RESULTS: Ninety-eight studies, involving 2,605,044 people, are included in this review. Fifty-four studies involving 812,705 people were comparable enough to be included in at least one meta-analysis. Thirty-five (65%) studies were RCTs. Nineteen (35%) of the studies included in the meta-analysis provided IPD. There was a lack of evidence that home safety interventions reduced rates of thermal injuries or poisoning. There was some evidence that interventions may reduce injury rates after adjusting CBA studies for baseline injury rates (IRR 0.89, 95% CI 0.78 to 1.01). Greater reductions in injury rates were found for interventions delivered in the home (IRR 0.75, 95% CI 0.62 to 0.91), and for those interventions not providing safety equipment (IRR 0.78, 95% CI 0.66 to 0.92). Home safety interventions were effective in increasing the proportion of families with safe hot tap water temperatures (OR 1.41, 95% CI 1.07 to 1.86), functional smoke alarms (OR 1.81, 95% CI 1.30 to 2.52), a fire escape plan (OR 2.01, 95% CI 1.45 to 2.77), storing medicines (OR 1.53, 95% CI 1.27 to 1.84) and cleaning products (OR 1.55, 95% CI 1.22 to 1.96) out of reach, having syrup of ipecac (OR 3.34, 95% CI 1.50 to 7.44) or poison control centre numbers accessible (OR 3.30, 95% CI 1.70 to 6.39), having fitted stair gates (OR 1.61, 95% CI 1.19 to 2.17), and having socket covers on unused sockets (OR 2.69, 95% CI 1.46 to 4.96). Interventions providing free, low cost or discounted safety equipment appeared to be more effective in improving some safety practices than those interventions not doing so. There was no consistent evidence that interventions were less effective in families whose children were at greater risk of injury.AUTHORS' CONCLUSIONS: Home safety interventions most commonly provided as one-to-one, face-to-face education, especially with the provision of safety equipment, are effective in increasing a range of safety practices. There is some evidence that such interventions may reduce injury rates, particularly where interventions are provided at home. Conflicting findings regarding interventions providing safety equipment on safety practices and injury outcomes are likely to be explained by two large studies; one clinic-based study provided equipment but did not reduce injury rates and one school-based study did not provide equipment but did demonstrate a significant reduction in injury rates. There was no consistent evidence that home safety education, with or without the provision of safety equipment, was less effective in those participants at greater risk of injury. Further studies are still required to confirm these findings with respect to injury rates.\n"}], "temperature": 0.0}}
{"custom_id": "R00009", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nEleven undescribed isoquinoline alkaloids (1-8, 14, 15, and 24), along with 19 analogues (9-13, 16-23, and 25-30) were isolated from the barks of Alangium salviifolium. The structures of the undescribed compounds were elucidated through the analysis of their HR-ESI-MS, 1D and 2D NMR, IR, UV, and X-ray diffraction. The absolute configuration of 8 was established via the ECD calculation. Notably, compounds 1/2 and 3/4 were two pairs of C-14 epimers. The isolated alkaloids were evaluated for their cytotoxicity against various cancer cell lines, including SGC-7901, HeLa, K562, A549, BEL-7402, HepG2, and B16, beta-carboline-benzoquinolizidine (14-22) and cepheline-type (24-28) alkaloids exhibited remarkable cytotoxicity, with IC50 values ranging from 0.01 to 48.12 mu M. Remarkably, compounds 17 and 21 demonstrated greater cytotoxicity than the positive control doxorubicin hydrochloride. Furthermore, a significant proportion of these bioactive alkaloids possess a C-1 ' epimer configuration. The exploration of their structure-activity relationship holds promise for directing future investigations into alkaloids derived from Alangium, potentially leading to novel insights and therapeutic advancements.\n"}], "temperature": 0.0}}
{"custom_id": "R00010", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nAims The purpose of this study was to investigate the effect of activated charcoal on the absorption of amlodipine, with special reference to delayed charcoal administration.Methods Thirty-two healthy volunteers, eight subjects in four parallel groups, ingested 10 mg of amlodipine on an empty stomach. Activated charcoal (25 g in 300 ml of water) was ingested either immediately afterwards or 2 h or 6 h after amlodipine, or amlodipine was ingested with 300 mi of water only (control). Plasma concentrations and the cumulative excretion of amlodipine into urine were measured by GC-MS for 96 h and 72 h, respectively. In addition, adsorption of amlodipine to charcoal was studied in vitro.Results Activated charcoal administered immediately after amlodipine reduced the amlodipine AUC(0,96 h) and the 72-h urinary excretion by 99% (P<0.0005). After a delay of 2 h in charcoal administration the AUC(0,96 h) was reduced by 49% (P=0.001), but after a delay of 6 h the reduction was 15% only (P=NS). At a charcoal:drug ratio of 5:1, about 90% of amlodipine was adsorbed by charcoal in vitro; at ratios of 10:1 and 20:1, adsorption was practically complete.Conclusions Activated charcoal almost completely prevented amlodipine absorption when administered immediately after amlodipine ingestion. Charcoal also markedly reduced amlodipine absorption when given 2 h after amlodipine; in amlodipine overdose, administration of charcoal may be beneficial even later. We conclude that administration of activated charcoal is the method of choice to prevent absorption of amlodipine in amlodipine overdose.\n"}], "temperature": 0.0}}
{"custom_id": "R00011", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nEthnopharmacological relevance: The health of nineteenth century Brazilians is only alluded to in historical documents, and researchers still have much to discover.Aim of the study: This study aims to show the medicinal plants used in the 19th century in Brazil.Materials and methods: To this end, information was obtained from the prescription book deposited in the archive of the Monastery of Saint Benedict in Olinda, Pernambuco, northeastern Brazil, about the daily use of medicinal plants. Results: By analyzing the prescriptions, we ascertained the terms and/or species and diseases and/or symptoms that existed among the people who were treated at the Benedictine hospital between 1823 and 1829.Conclusions: The data presented here are relevant to other subject areas, especially modern pharmaceutical research. This study seeks to demonstrate the importance of plant resources in the nineteenth century and aims, through the detailed study of documentary sources, to provide a wealth of new information to modern science. Understanding the practices of the past provides insight into and may lead to improvements in modern pharmaceutical practice. (C) 2011 Elsevier Ireland Ltd. All rights reserved.\n"}], "temperature": 0.0}}
{"custom_id": "R00012", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nBackground: Activated charcoal (AC) is commonly used for the routine management of oral drug overdose.Aim: To determine whether the routine use of activated charcoal has an effect on patient outcomes.Design: Randomized controlled unblinded trial.Methods: We recruited all adult patients presenting with an oral overdose at The Canberra Hospital, excluding only transfers, late presenters, those who had ingested drugs not adsorbed by activated charcoal or where administration was contraindicated, and very serious ingestions (at the discretion of the admitting physician). Patients were randomized to either activated charcoal or no decontamination.Results: The trial recruited 327 patients over 16 months. Of 411 presentations, four refused consent, 27 were protocol violations and 53 were excluded from the trial. Only seven were excluded due to the severity of their ingestion. The most common substances ingested were benzodiazepines, paracetamol and selective serotonin reuptake inhibitor antidepressants. More than 80% of patients presented within 4 h following ingestion. There were no differences between AC and no decontamination in terms of length of stay (AC 6.75 h, IQR 4-14 vs. controls 5.5 h, IQR 3-12; p = 0.11) or secondary outcomes including vomiting, mortality and intensive care admission.Discussion: Routine administration of charcoal following oral overdose did not significantly influence length of stay or other patient outcomes following oral drug overdose. There were few adverse events. This does not exclude a role in patients who present shortly after ingestion of highly lethal drugs.\n"}], "temperature": 0.0}}
{"custom_id": "R00013", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nApomorphine, a centrally-acting emetic, was administered subcutaneously (50 micrograms/kg) to nine normal subjects (four male, five female; aged 22-36 years) and four patients with idiopathic diabetes insipidus (DI) (one male, three female; aged 24-49 years). In the normal subjects this stimulus caused nausea (and vomiting in seven of nine) with a latency of 9.5 +/- 0.9 min which was followed by a large increase in plasma arginine vasopressin (AVP) concentration (from 0.9 +/- 0.2 pmol/l to 249 +/- 104 pmol/l at 15 min after the onset of symptoms; mean +/- SEM, P less than 0.01). There was a small but significant increase in plasma oxytocin (OXT) concentration (from 1.6 +/- 0.4 pmol/l to 6.2 +/- 3.4 pmol/l; P less than 0.05). Mean arterial pressure (MAP) fell slightly (from 87 +/- 1.9 mm Hg to 71 +/- 4.4 mm Hg; P less than 0.05) 15 min after the onset of nausea; there was no change in blood haematocrit or plasma osmolality and sodium concentration. In the DI patients apomorphine produced nausea (with vomiting in three of four) with a latency of 10.0 +/- 1.4 min but failed to cause an increase in either plasma AVP or OXT. In the DI patients the fall in MAP did not reach statistical significance (83 +/- 4 mm Hg to 71 +/- 11 mm Hg); there was also no change in haematocrit, osmolality or sodium concentration. Ipecacuanha, an emetic with both peripheral and central actions, was administered orally to seven normal subjects (three male, four female; aged 22-36 years) six of whom also underwent apomorphine tests.(ABSTRACT TRUNCATED AT 250 WORDS)\n"}], "temperature": 0.0}}
{"custom_id": "R00014", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\n1. The cardiotoxic effects of emetine dihydrochloride on mechanical and electrical activity were studied in isolated preparations (papillary muscles, sinoatrial and atrioventricular nodes, ventricular myocytes) of the guinea-pig heart. 2. Force of contraction was measured isometrically, action potentials and maximum rate of rise of the action potential were recorded by means of the intracellular microelectrode technique. Single channel L-type calcium current (Ba2+ ions as charge carrier) was studied with the patch-clamp technique in the cell-attached mode. 3. Emetine dihydrochloride (8-256 microM) reduced force of contraction in papillary muscles and spontaneous activity of sinoatrial and atrioventricular nodes concentration-dependently; the negative inotropic effect was abolished when the extracellular Ca2+ concentration was increased. 4. Maximum diastolic potential, action potential amplitude, maximum rate of rise of the action potential and the slope of the slow diastolic depolarization were decreased by emetine in sinoatrial as well as atrioventricular noes, while action potential duration was prolonged in both preparations (1-64 microM). 5. The amplitude of the L-type calcium single channel current was not altered by emetine dihydrochloride, while average open state probability was decreased concentration-dependently (10, 30 and 60 microM). 6. The most prominent effect of emetine dihydrochloride on single channel current was an increase of sweeps without activity. 7. At 60 microM, emetine dihydrochloride caused a decrease of the mean open time an increase of the mean closed time. The number of openings per record and number of bursts per record were reduced. 8. It is concluded that emetine dihydrochloride produces an L-type calcium channel block which might contribute to its cardiac side effects.\n"}], "temperature": 0.0}}
{"custom_id": "R00015", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nBackground: The purpose of this study was to evaluate if propofol has 5-HT3 antagonistic effects. Ipecacuanha is known to release serotonin (5-HT) in the gastrointestinal tract and therefore ipecacuanha syrup was used to induce nausea and vomiting. The 5-HT3 antagonist ondansetron was used as a control substance.Method: Ten healthy male volunteers (20-37 years) were studied on three occasions and were randomly allocated to receive a concomitant infusion of propofol (initial bolus 0.1 mg kg(-1) then 1 mg kg(-1)h(-1)), ondansetron (initial bolus 0.11 mg kg(-1) then 14 mu g kg(-1)h(-1)) and placebo on either occasion. The infusions started 30 min before oral ingestion of 30 ml of ipecacuanha and continued until 150 min after the intake. The number of retchings was recorded and the intensity of nausea was estimated by the subjects on a visual analog scale.Results: During the first 150 min after ingestion of ipecacuanha there were no retchings during the ondansetron infusion (P=0.01 vs placebo, P=0.02 vs propofol) and significantly fewer retchings during propofol infusion compared to placebo (P<0.02). There was no nausea during the ondansetron infusion (P<0.01 vs placebo and propofol) but the volunteers experienced nausea both during the placebo and propofol infusion gus).Conclusion: This study in volunteers has shown that propofol reduces the intensity of retching after oral intake of ipecacuanha syrup. As ipecacuanha releases 5-hydroxytryptamine, it can be concluded that propofol may have a weak 5-HT3 antagonistic effect.\n"}], "temperature": 0.0}}
{"custom_id": "R00016", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nAims The aim was to study the efficacy of gastric lavage and activated charcoal in preventing the absorption of temazepam, verapamil and moclobemide when gastric decontamination was performed immediately after ingestion of the drugs.Methods Nine healthy volunteers took part in a randomized cross-over study with three phases. The subjects were administered single oral doses of 10 mg temazepam, 80 mg verapamil and 150 mg moclobemide. Five minutes later, they were assigned to one of the following treatments: 200 ml water (control), 25 g activated charcoal as a suspension in 200 ml water or gastric lavage. Plasma concentrations and the cumulative excretion into urine of the three drugs were determined up to 24 h.Results The mean AUC(0,24 h) of temazepam, verapamil and moclobemide was reduced by 95.2% (P < 0.01), 92.8% (P < 0.01) and 99.7% (P < 0.01), respectively, by activated charcoal compared with control. Gastric lavage did not reduce significantly the AUC(0,24 h) of these drugs. The 24 h cumulative excretion of temazepam, verapamil and moclobemide into urine was reduced significantly (P < 0.05) by charcoal but not by gastric lavage. Charcoal reduced the AUC(0,24 h), C-max and urinary excretion of all three drugs significantly more than lavage.Conclusions Activated charcoal is very effective and gastric lavage can be rather ineffective in preventing the absorption of temazepam, verapamil and moclobemide when the treatment is given very rapidly after ingestion of the drugs, before tablet disintegration has occurred.\n"}], "temperature": 0.0}}
{"custom_id": "R00017", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nPsychotria ipecacuanha is a perennial, medicinal herb that grows in clusters in the understory of humid, shady areas of the Atlantic Rain Forest of southeastern Brazil. The present study characterized the variation in floral traits among 35 clusters from three natural populations of this plant species. Field observations showed that the clusters are isomorphic, that is, a given cluster will either set long-styled or short-styled flowers. Stigmas and anthers are reciprocally placed in each morph, a dimorphism characteristic of distyly. The populations are isoplethic, that is, a given population exhibits an equilibrium 1:1 ratio of floral morphs. Morphometric analyses revealed that anther length, stigma length, corolla diameter, and pollen grain diameter were consistently greater in short-styled flowers, regardless of the population investigated. Significant differences for floral traits in the short-styled morph were found among populations. Floral traits in the long-styled morph also showed some significant differences among populations, but not for stigma height and corolla length. Controlled pollinations carried out in natural populations showed that fruit production was higher after inter-morph pollination. Nevertheless, observations of pollen tube growth in style, and also fruit production after spontaneous self-pollination and intra-morph pollination, indicated partial intramorph compatibility in this plant species.\n"}], "temperature": 0.0}}
{"custom_id": "R00018", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nPurpose: To determine the maximum-tolerated dose and characterize the pharmacokinetic behavior of LU79553, a novel bisnaphthalimide antineoplastic agent, when administered as a daily intravenous infusion for 5 days every 3 weeks.Patients and Methods: Patients with advanced solid malignancies received escalating doses of LU79553. plasma sampling and urine collections were performed on both days 1 and 5 of the first course.Results: Thirty patients received 105 courses of LU79553 at doses ranging from 2 to 24 mg/m(2)/d. Proximal myopathy, erectile dysfunction, and myelosuppression precluded the administration of multiple courses at doses above 18 mg/m(2)/d. These toxicities were intolerable in two of six patients after receiving three courses at the 24-mg/m(2)/d dose level. At the 18-mg/m(2)/d dose, one of six patients developed febrile neutropenia and grade 2 proximal myopathy after three courses of LU79553. The results of electrophysiologic, histopathologic, and ultrastructural studies supported a drug-induced primary myopathic process. A patient with a platinum- and taxane resistant papillary serous carcinoma of the peritoneum experienced a partial response lasting 22 months. Pharmacokinetics were dose-independent, optimally described by a three-compartment model, and there was modest drug accumulation over the 5 days of treatment.Conclusion: Although no dose-limiting events were noted in the first two courses of LU79553, cumulative muscular toxicity precluded repetitive treatment with LU79553 at doses above 18 mg/m(2)/d, which is the recommended dose for subsequent disease-directed evaluations. the preliminary antitumor activity noted is encouraging, but the qualitative and cumulative nature of the principal toxicities, as well as the relatively small number of patients treated repetitively, mandate that rigorous and long-term toxicologic monitoring be performed in subsequent evaluations of this unique agent. (C) 2001 by American Society of Clinical Oncology.\n"}], "temperature": 0.0}}
{"custom_id": "R00019", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nIpecacuanha syrup induces emesis by an early peripheral (gastric irritant) action and a later central effect at the chemoreceptor trigger zone (CTZ). We have studied the responses of plasma AVP, ACTH and ACTH-precursors to early and late ipecacuanha-induced nausea in nine healthy male subjects. Symptom severity was assessed using a linear analogue scale. All subjects reported 'early' nausea (N1) with a latency of 16 +/- 2 min (mean +/- SEM) and eight subjects vomited. Six subjects experienced recurrent nausea (N2) (latency 106 +/- 10.4 min) of whom five also vomited. The interval between the cessation of N1 and the onset of N2 was 55 +/- 10.8 min (range 25-80 min). The severity of nausea at the onset of N1 or N2 was similar but the AVP and ACTH responses were highly variable. Thus, while mean plasma AVP concentrations increased during both symptom periods, in three subjects during N1 and in three subjects during N2 plasma AVP concentrations did not rise above the normal range, despite marked symptoms. No clear pattern of AVP response to distinguish early peripheral from late central ipecacuanha-induced emesis was demonstrated. Whilst mean plasma ACTH concentrations increased during both N1 and N2 there were no changes in mean plasma ACTH-precursor concentrations. Analysis of pooled data for N1 and N2 demonstrated direct correlations between the nausea score and the peak incremental plasma responses of either AVP or ACTH and, despite the variability, peak incremental concentrations of AVP and of ACTH were also correlated. The data indicate that there is no difference in the AVP responses to peripherally or centrally stimulated ipecacuanha-induced nausea.(ABSTRACT TRUNCATED AT 250 WORDS)\n"}], "temperature": 0.0}}
{"custom_id": "R00020", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\n1 We have carried out a prospective study of all adult patients presenting with acute poisoning during one month to the Helsinki University Central Hospital (Meilahti Hospital).2 Two hundred and twenty-six cases of acute poisoning (113 males and 113 females) presented to the emergency department. Most cases in both men (66%) and women (67%) involved alcohol. As to drugs, psychotropic agents predominated in both men and women. The frequency of patient presentation peaked between 7 p.m. and 9 p.m. and was lowest between 8 a.m. and 10 a.m. In most cases, the delay from ingestion of the poison to presentation was longer than 4 h.3 The clinical status of the patients on arrival was generally good; more than half (55%) of them were fully awake. Serious symptoms (e.g. unconsciousness, insufficient respiration necessitating intubation, aspiration, convulsions or hypotension) occurred in 15% of the presentations. There were no fatalities.4 One hundred and thirty-five patients (60%) received at least one 50-g dose of activated charcoal. However, charcoal was given in 86% of the cases of drug poisoning. Gastric lavage was performed in 112 cases (50%), and 106 cases (47%) involved both gastric lavage and administration of charcoal. Twenty-one patients received antidotes (flumazenil, calcium gluconate or naloxone) and three patients were hemodialysed.5 Of the 226 cases, 142 (63%) were managed solely in the emergency department. Of the 84 cases admitted to the hospital, eight had to be managed in the intensive care unit. Almost all patients (94%) were discharged within 24 h.6 In this survey on 226 consecutive cases of acute poisoning, about two-thirds of the cases involved alcohol, while the most common drugs taken were psychotropic agents. The poisoning was mild in the great majority of the cases. Activated charcoal was generally administered in all but trivial cases of drug poisoning.\n"}], "temperature": 0.0}}
{"custom_id": "R00021", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nEpidemiologic data on poisonings in Turkey are extremely limited. This is a retrospective chart review to describe the prevalence of poisoning in both adults and children, the presenting clinical features, morbidity and mortality to identify how poisoning in Izmir follows the pattern of other countries and how it is unique. Three hundred sixty-five poisoned patients presented to the Dokuz Eylul University Hospital, Ismir in 1989 to 1990. The distribution frequency of substances ingested reflects that of substances available in the home. Poisoning episodes in small children were most likely to involve hydrocarbons, analgesic, caustics or pesticides (55%). Ethanol, anticonvulsants, tricyclic antidepressants, and pesticides (55%). Ethanol, anticonvulsants, tricyclic antidepressants, and pesticides were the most common toxins seen in adults. A significant number of patients presented late in the course of their poisoning. Of those ingesting pharmaceuticals, mushrooms or plants, emesis, but no other modes of decontamination, was reported for 21%. Toxin antidotes, gastrointestinal decontamination and enhanced drug removal techniques used in other parts of the world were rarely utilized. Nonetheless, only three patients (0.8%) died. This pilot study supports the need for a Regional Poison Information Center offering poison management advice to the general public as well as to members of the health care professions, the initiation of a public education campaign, and regional treatment by physicians trained in medical toxicology.\n"}], "temperature": 0.0}}
{"custom_id": "R00022", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nBackground: Corticosteroids reduce the incidence of PONV but the mode of action is not known. The purpose of this study was to evaluate if betamethasone has serotonin (5-HT) antagonistic effects. Ipecacuanha is known to release serotonin and therefore it was used to induce nausea and vomiting. The 5-HT3 antagonist ondansetron was used as a control substance.Methods: In a randomized, double-blind, cross-over, placebo-controlled study 10 healthy male and female volunteers (6 M/4F), mean age 19.5 (18-23) years, mean weight 69.7 (53-84) kg, were studied on three occasions separated by at least 1 week. They were randomly allocated to receive pretreatment with betamethasone 8 mg, ondansetron 8 mg, or normal saline 2 ml as placebo on each occasion, 15 min before oral ingestion of 30 ml of Ipecacuanha syrup. After ingestion of ipecacuanha, vomitings were recorded and the intensity of nausea was estimated with a visual analog scale during 2 h.Results: During the first 2 h after ingestion of ipecacuanha nine of the 10 volunteers vomited both after betamethasone and placebo. No volunteer vomited after ondansetron (P < 0.01 vs. betamethasone and placebo). The max VAS for nausea was significantly higher after betamethasone and placebo compared to ondansetron (P < 0.01). There were no statistically significant differences of the max VAS for nausea between betamethasone and placebo.Conclusion: This study in volunteers has shown that betamethasone does not prevent nausea and vomiting induced by oral intake of ipecacuanha syrup. As ipecacuanha releases 5-hydroxytryptamin, it can be concluded that betamethasone does not have 5-HT3 antagonistic effects.\n"}], "temperature": 0.0}}
{"custom_id": "R00023", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nBackground: A randomized double-blind placebo controlled clinical study was undertaken to investigate the safety and efficacy of a plant-based formulation (DCBT1234-Lung KR), which earlier through 2 trials was found to improve FEV1 and the quality of life of COPD patients.Objective: The efficacy of DCBT1234-Lung KR was assessed using pulmonary function tests, arterial blood gas (ABG) analyses and the clinical symptoms of COPD in a 6-month study period against a matching placebo and a biomedical drug combination (salbutamo+theophylline+bromhexine).Methods: One hundred and five subjects aged between 35 and 85 years with a smoking history of more than 20 pack years, showing Little or no improvement in FEV, upon a bronchial challenge of 200 mu g of inhaled salbutamol and exhibiting ABG percentage of less than 85% of oxygen saturation were taken up for the study. The study had 3 arms viz., the plant-based formulation (DCBT1234-Lung KR), placebo and salbutamol (12mg/day) plus theophylline (300mg/day) plus bromhexine (24mg/ day). The end point of the study was determined as an improvement of FEV1 by 200mL and/or increased ABG values (>90% PaO2) and clinical symptoms like dyspnoea, wheezing, cough, expectoration, disability, and steep disturbances.Results: DCBT1234-Lung KR patients showed statistically significant (95% level) improvement in FEV1 and PaO2 in comparison with salbutamol+theophyttine+bromhexine and placebo patients. Twenty-three per cent of DCBT1234-Lung KR patients, 19% of salbutamol+theophylline+bromhexine group and 12% of placebo group patients showed the desired 200 mL improvement in FEV1 values in comparison with the other 2 arms. Improved PaO2 was observed in 15.4% of the DCBT1234-Lung KR patients white no improvement was seen with patients in any other arms. Symptoms like dyspnoea, wheezing, cough, expectoration, disability and steep disturbances also significantly reduced in DCBT1234-Lung KR and the biomedical group patients, but not in the placebo arm.Conclusions: DCBT1234-Lung KR was equivalent, if not better than the present day treatment with salbutamol, theophylline and bromhexine combination in COPD patients and this was ascertained using FEV1 and ABG values. (c) 2005 Elsevier Ltd. All rights reserved.\n"}], "temperature": 0.0}}
{"custom_id": "R00024", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nAbuse of widely available, over-the-counter drugs and supplements such as laxatives and diet pills for weight control by youths is well documented in the epidemiological literature. Many such products are not medically recommended for healthy weight control or are especially susceptible to abuse, and their misuse can result in serious health consequences.We analyzed the government's role in regulating these products to protect public health. We examined federal and state regulatory authority, and referred to international examples to inform our analysis. Several legal interventions are indicated to protect youths, including increased warnings and restrictions on access through behind-the-counter placement or age verification.We suggest future directions for governments internationally to address this pervasive public health problem. (Am J Public Health. 2013;103:220-225. doi:10.2105/AJPH.2012.300962)\n"}], "temperature": 0.0}}
{"custom_id": "R00025", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nAims Activated charcoal is now being recommended Cor patients who have ingested Potentially toxic amounts of a poison, where the ingested substance adsorbs to charcoal. Combination therapy with gastric lavage and activated charcoal is widely used, although clinical studies to date have not provided evidence of additional efficacy compared with the use of activated charcoal alone. There Lire also doubts regarding the efficacy of activated charcoal, when administered more than 1 h after the overdose. The aim of this study was to examine if there was a difference in the effect of the two interventions 1 h post ingestion, and to determine if activated charcoal was effective in reducing the systemic absorption of a drug, when administered 2 h post ingestion.Methods We performed a four-limbed randomized cross-over study in 12 volunteer, who 1 h after a standard meal ingested paracetamol 50 mg kg(-1) in 125 mg tablets to mimic real-life, where several factors, such as food, interfere with gastric emptying and thus treatment. The interventions were activated charcoal after 1 h, combination therapy of gastric lavage followed by activated charcoal after I h, or activated charcoal after 2 h. Serum paracetamol concentrations were determined by h.p.l.c. Percentage reductions in the area under the curve (AUC) were used to estimate the efficacy of each intervention (paired observations).Results There was a significant (P<0.005) reduction in the paracetamol AUC with activated charcoal at 1 h (median reduction 66%, 95% confidence intervals 49, 70) compared with controls, and a significant (P<0.01) reduction for gastric lavage followed by activated charcoal at 1 h (median reduction 48.2%, 95% confidence interval 32.4, 63.7) compared with controls. There was no significant difference between the two interventions (95% confidence interval for the difference -3.8, 34.0). Furthermore, v,,e found a significant (P<0.01) reduction in the paracetamol AUC when activated charcoal was administered 2 11 after tablet ingestion when compared with controls (median 22.7%, 95% confidence intervals 13.y-34.4).Conclusions These results suggest that combination treatment may be no better than activated charcoal alone in patients presenting early after large overdoses. The effect of activated charcoal given 2 h post ingestion is substantially less than at 1 h, emphasizing the importance of early intervention.\n"}], "temperature": 0.0}}
{"custom_id": "R00026", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nBACKGROUND There is an urgent need to develop new agents for treating metastatic prostate cancer to overcome multiple drug resistance to the current standard targeted cancer therapy. Emetine is a highly cytotoxic natural product protein synthesis inhibitor, which is toxic to all cell types. Its cytotoxicity can be blocked by derivatizing its N-2 position. Thus emetine can be selectively delivered to cancer cells in the region of metastatic cancer as a prodrug that will be activated by an enzyme selectively overexpressed within the metastatic tumor microenvironment. In this work, we convert emetine to a prodrug activatable by the fibroblast activation protein (FAP), a serine protease overexpressed by the carcinoma associated fibroblasts.METHOD By using an iterative structure-activity relationship strategy, several peptidyl emetine prodrug analogs (1-11) were synthesized by chemical derivatization of emetine at its N-2 position and tested for in-vitro activation by FAP. The lead prodrug 11 is made up of a DPPIV activatable prodrug precursor 10 (Ala-Pro-PABC-Emetine) coupled to FAP substrate (Ala-Ser-Gly-Pro-Ala-Gly-Pro). Activation assays of the prodrugs were performed in purified FAP, DPPIV, FBS, and human serum and were analyzed by LCMS. In vitro cytotoxicity assays of these prodrugs are carried out in prostate (LNCaP, PC3) and breast (MCF7 and MDA-MB-231) cancer cell lines. The prodrugs are also tested in normal immortalized human prostatic epithelial cell line (PrEC).RESULTS The lead FAP activated emetine prodrug 11 is activated to emetine in tandem by FAP and DPPIV in about 70% conversion within 24hr. In prostate and breast cancer cell lines treated with prodrug 11, it is found to be equipotent with emetine in the presence of FAP and DPPIV. However, in the PrEC cell line grown in serum free media, prodrug 11 is more than 200-fold less cytotoxic than emetine in the absence of FAP and DPPIV.CONCLUSION This FAP activated prodrug of cytotoxic agent emetine further shows the crucial role of the N-2 position of emetine in controlling its cytotoxicity. Significantly reduced toxicity observed in the PrEC cell line in the absence of FAP and DPPIV shows that prodrug 11 could be systemically delivered to regions of metastatic prostate cancer or other solid tumor for activation by cancer selective enzymes within the cancer microenvironment, such as FAP that is overexpressed by the carcinoma-associated fibroblasts. The two-step tandem enzymatic activation of prodrug 11 by FAP and DPPIV is a strategy for overcoming steric hindrance. (C) 2016 Wiley Periodicals, Inc.\n"}], "temperature": 0.0}}
{"custom_id": "R00027", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nSalsolinol, a tetrahydroisoquinoline present in the human and rat brains, is the condensation product of dopamine and acetaldehyde, the first metabolite of ethanol. Previous evidence obtained in vivo links salsolinol with the mesolimbic dopaminergic (DA) system: salsolinolis self-administered into the posterior of the ventral tegmental area (pVTA) of rats; intra-VTA administration of salsolinol induces a strong conditional place preference and increases dopamine release in the nucleus accumbens (NAc). However, the underlying neuronal mechanisms are unclear. Here we present an overview of some of there centre search on this topic. Electrophysiological studies reveal that DA neurons in the pVTA are a target of salsolinol. In acute brain slices from rats, salsolinol increases the excitability and accelerates the ongoing firing of dopamine neurons in the pVTA. Intriguingly, this action of salsolinol involves multiple pre- and post-synaptic mechanisms, including: (1) depolarizing dopamine neurons; (2) by activating mu opioid receptors on the GABAergic inputs to dopamine neurons - which decreases GABAergic activity-dopamine neurons are disinhibited; and(3) enhancing presynaptic glutamatergic transmission on to dopamine neurons via activation of dopamine type 1 receptors, probably situated on the glutamatergic terminals. These novel mechanisms may contribute to there warding/reinforcing properties of salsolinol observed in vivo.\n"}], "temperature": 0.0}}
{"custom_id": "R00028", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nA series of 3 -alkyl-7 -substituted-1,2,3,4-tetrahydroisoquinolines was synthesized and these compounds were evaluated for their PNMT inhibitory potency and affinity for the (alpha(2)-adrenoceptor. 7-Nitro-, 7-bromo-, 7-aminosulfonyl-, or 7-N-2,2,2-trifluoroethylaminosulfonyl-THIQs that possess a 3-alkyl substituent that is longer than a methyl group showed decreased PNMT inhibitory potency, except for 3-propyl-7-aminosulfonyl-THIQ, which displayed excellent PNMT inhibitory potency. The rank order for selectivity (PNMT vs the alpha(2)-adrenoceptor) is 3 -alkyl -7 -aminosulfonyl-THIQs congruent to 3-alkyl-7-N-2,2,2-trifluoroethylaminosulfonyl-THIQs > 3-alkyl-7-nitro-THlQs > 3-alkyl-7-bromo-THIQs. (C) 2004 Elsevier Ltd. All rights reserved.\n"}], "temperature": 0.0}}
{"custom_id": "R00029", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nThe mechanisms of the positive inotropic action of a new synthetic tetrahydroisoquinoline compound, SL-1, were investigated in isolated rat cardiac tissues and ventricular myocytes. SL-1 produced a rapidly developing, concentration-dependent positive inotropic response in both atrial and ventricular muscles and a negative chronotropic effect in spontaneously beating right atria. The positive inotropic effect was not prevented by pretreatment with reserpine (3 mg/kg) or the alpha-adrenoceptor antagonist prazosin (1 microM), but was suppressed by either the beta-adrenoceptor antagonist atenolol (3 microM) or the K+ channel blocker 4-aminopyridine (4AP, 1mM). In the whole-cell recording study, SL-1 increased the plateau level and prolonged the action potential duration in a concentration-dependent manner and decreased the maximum upstroke velocity (Vmax) and amplitude of the action potential in isolated rat ventricular myocytes stimulated at 1.0 Hz. On the other hand, SL-1 had little effect on the resting membrane potential, although it caused a slight decrease at higher concentrations. Voltage clamp experiments revealed that the increase of action potential plateau and prolongation of action potential duration were associated with an increase of Ca2+ inward current (ICa) via the activation of beta-adrenoceptors and a prominent inhibition of 4AP-sensitive transient outward K+ current (Ito) with an IC50 of 3.9 microM. Currents through the inward rectifier K+ channel (IK1) were also reduced. The inhibition of Ito is characterized by a reduction in peak amplitude and a marked acceleration of current decay but without changes on the voltage dependence of steady-state inactivation. In addition to the inhibition of K+ currents, SL-1 also inhibited the Na+ inward current (INa) with an IC50 of 5.4 microM, which was correlated with the decrease of Vmax. We conclude that the positive inotropic effect of SL-1 may be due to an increase in Ca2+ current mediated via partial activation of beta-adrenoceptors and an inhibition of K+ outward currents and the subsequent prolongation of action potentials.\n"}], "temperature": 0.0}}
{"custom_id": "R00030", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nOn the basis of X-ray crystallographic studies of the complex of hCA II with 4-(3,4-dihydro-1H-isoquinoline-2-carbonyl)benzenesulfonamide (3) (PDB code 4Z1J), a novel series of 4-(1-aryl-3,4-dihydro-1H-isoquinolin-2-carbonyl)-benzenesulfonamides (23-33) was designed. Specifically, our idea was to improve the selectivity toward druggable isoforms through the introduction of additional hydrophobic/hydrophilic functionalities. Among the synthesized and tested compounds, the (R,S)-4-(6,7-dihydroxy-1-phenyl-3,4-tetrahydroisoquinoline-1H-2-carbonyl)benzenesulfonamide (30) exhibited a remarkable inhibition for the brain-expressed hCA VII (K-i = 0.20 nM) and selectivity over wider distributed hCA I and hCA II isoforms. By enantioselective HPLC, we solved the racemic mixture and ascertained that the two enantiomers (30a and 30b) are equiactive inhibitors for hCA VII. Crystallographic and docking studies revealed the main interactions of these inhibitors into the carbonic anhydrase (CA) catalytic site, thus highlighting the relevant role of nonpolar contacts for this class of hCA inhibitors.\n"}], "temperature": 0.0}}
{"custom_id": "R00031", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nAlthough Dr Merton Sandler's extensive and vigorous research program over the years has been concerned mainly with classical biogenic amines, monoamine oxidase (MAO), and MAO inhibitors, he and his group contributed a significant early Parkinson's disease-related study of a non-classical or aberrant biogenic amine. The formation and production of this amine, the dopamine-derived mammalian alkaloid, tetrahydropapaveroline (THP), is in fact dependent on MAO activity. As reviewed here, that study provided the groundwork for and indeed stimulated many later investigations of mammalian alkaloids in numerous laboratories around the world. (C) 2003 Elsevier Inc. All rights reserved.\n"}], "temperature": 0.0}}
{"custom_id": "R00032", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nCovering: 2015 to 2020 Nitrogen heterocyclic natural products (NHNPs) are primary or secondary metabolites containing nitrogen heterocyclic (N-heterocyclic) skeletons. Due to the existence of the N-heterocyclic structure, NHNPs exhibit various bioactivities such as anticancer and antibacterial, which makes them widely used in medicines, pesticides, and food additives. However, the low content of these NHNPs in native organisms severely restricts their commercial application. Although a variety of NHNPs have been produced through extraction or chemical synthesis strategies, these methods suffer from several problems. The development of biotechnology provides new options for the production of NHNPs. This review introduces the recent progress of two strategies for the biosynthesis of NHNPs: enzymatic biosynthesis and microbial cell factory. In the enzymatic biosynthesis part, the recent progress in the mining of enzymes that synthesize N-heterocyclic skeletons (e.g., pyrrole, piperidine, diketopiperazine, and isoquinoline), the engineering of tailoring enzymes, and enzyme cascades constructed to synthesize NHNPs are discussed. In the microbial cell factory part, with tropane alkaloids (TAs) and tetrahydroisoquinoline (THIQ) alkaloids as the representative compounds, the strategies of unraveling unknown natural biosynthesis pathways of NHNPs in plants are summarized, and various metabolic engineering strategies to enhance their production in microbes are introduced. Ultimately, future perspectives for accelerating the biosynthesis of NHNPs are discussed.\n"}], "temperature": 0.0}}
{"custom_id": "R00033", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nVisible-light-driven hydrogen production coupled with selective organic oxidation has attracted increasing attention, as it not only provides clean and renewable energy, but also utilizes the other half reaction to achieve some value-added organic chemicals. Metal-organic frameworks based on metal clusters and organic ligands self-assembly give a perspective on the formation of multifunctional heterogeneous photocatalyst to significantly boost visible-light photocatalytic activities under mild conditions. By incorporating two types of photoactive units, tricarboxytriphenylamine (H(3)TCA) and tris(4-(pyridinyl)phenyl)amine (NPy3), into a single metal-organic frameworks, a multi-component MOF Co-MIX was obtained. With the redox active metal centers enabling the photoexcitation reduction of protons into hydrogen and the photogenerated holes promoting considerable oxidation of substrates, the resulting Co-MIX exhibits high catalytic activity for the photocatalytic hydrogen production coupled with selective oxidation of benzylamine or 1,2,3,4-tetrahydroisoquinoline. Importantly, the photocatalytic experiments of single-component Co-TCA and Co-NPy3 verified the positive synergistic effects on stability and photocatalytic ability of the two ligands (H(3)TCA and NPy3) in one single MOF, revealing that the multi-component strategy is very important for the efficient charge separation and excellent photocatalytic activity of the catalyst.\n"}], "temperature": 0.0}}
{"custom_id": "R00034", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nTrimetoquinol [1-(3',4',5'-trimethoxybenzyl)-6,7-dihydroxy-1,2,3,4- tetrahydroisoquinoline , TMQ] exists as two enantiomers, and the (-)-(S)-isomer is a potent beta-adrenergic receptor (beta-AR) agonist. Experiments were conducted to examine the functional and biochemical potencies of the (S)-and (R)-enantiomers of TMQ for interaction with beta-AR subtypes in tissues, membrane fractions, and cell systems. The isomeric-activity ratios (IARs) of the TMQ isomers [(S)-isomer > > (R)-isomer] for stimulation of beta 1- and beta 2-AR of guinea pig right atria and trachea were 224 and 1585, respectively; these IARs were similar to those observed on atypical beta-AR systems of rat distal colon (575), rat brown adipocytes (398), but differed from that of rat esophageal smooth muscle (2884) in the presence of pindolol. In the absence of pindolol, the potencies for the TMQ enantiomers were slightly increased; however, the IARs remained unchanged in rat distal colon, rat brown adipocytes, and rat esophageal smooth muscle. Similarly, radioligand binding studies demonstrated that the TMQ isomer beta-AR affinities were stereoselective for the (-)-(S)-isomer in membranes of guinea pig left ventricle (beta 1) and lung (beta 2) giving IARs of 115 and 389, respectively; and in E. coli expressing human beta 1- and beta 2-AR giving IARs of 661 and 724, respectively. Corresponding IARs of receptor affinities and stimulation of cAMP accumulation in Chinese hamster ovary cells expressing human beta 2-AR and rat beta 3-AR were 331 and 282, and 118 and 4678, respectively. These results indicate that the (-)-(S)-isomer of TMQ exhibits high affinity, and is a potent and highly stereoselective agonist for each beta-AR subtype, that the isomers generally fail to differentiate between the beta-AR subtypes, and that, based upon differences in IAR within beta 3-AR containing systems, subtypes of atypical beta (or beta 3)-AR may exist in adipose tissue and smooth muscle.\n"}], "temperature": 0.0}}
{"custom_id": "R00035", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nIn this study, we disclose the outcomes of the biological assessment of recently synthesized hybrids of ketoprofen with 2-phenylethylamines and 1,2,3,4tetrahydroisoquinolines. These hybrids were obtained using an environmentally friendly method that minimizes the generation of waste products. The newly acquired hybrids were analysed to evaluate their antioxidant, anti-inflammatory, and anti -arthritic activities. Additionally, as potential drugs exhibiting favourable results, their experimental partition coefficient in a biphasic system of lipids and water (logP) was determined.\n"}], "temperature": 0.0}}
{"custom_id": "R00036", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nAlkaloids are a class of organic compounds with a wide range of biological properties, including anti-HIV activity. The 1,2,3,4-tetrahydroisoquinoline is a ubiquitous structural motif of many alkaloids. Using a short and an efficient route for synthesis, a series of 1,2,3,4-tetrahydroisoquinolines/isoquinolines was developed. These compounds have been analysed for their ability to inhibit an important interaction between HIV-1 integrase enzyme (IN) and human LEDGF/p75 protein (p75) which assists in the viral integration into the active genes. A lead compound 6d is found to inhibit the LEDGF/p75-IN interaction in vitro with an IC50 of similar to 10 mu m. Molecular docking analysis of the isoquinoline 6d reveals its interactions with the LEDGF/p75-binding residues of IN. Based on an order of addition experiment, the binding of 6d or LEDGF/p75 to IN is shown to be mutually exclusive. Also, the activity of 6d in vitro is found to be unaffected by the presence of a non-specific DNA. As reported earlier for the inhibitors of LEDGF/p75-IN interaction, 6d exhibits a potent inhibition of both the early and late stages of HIV-1 replication. Compound 6d differing from the known inhibitors in the chemical moieties and interactions with CCD could potentially be explored further for developing small molecule inhibitors of LEDGF/p75-IN interaction having a higher potency.\n"}], "temperature": 0.0}}
{"custom_id": "R00037", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nInhibition of monoamine oxidase is one way to treat depression and anxiety. The information now available on the pharmacokinetics of flavonoids and of the components of tobacco prompted an exploration of whether a healthy diet (with or without smoking) provides active compounds in amounts sufficient to partially inhibit monoamine oxidase. A literature search was used to identify dietary monoamine oxidase inhibitors, the levels of these compounds in foods, the pharmacokinetics of the absorption and distribution, and tissue levels observed. An estimated daily intake and the expected tissue concentrations were compared with the measured efficacies of the compounds as inhibitors of monoamine oxidases. Norharman, harman and quercetin dietary presence, pharmacokinetics, and tissue levels were consistent with significant levels reaching neuronal monoamine oxidase from the diet or smoking; 1,2,3,4-tetrahydroisoquinoline, eugenol, 1-piperoylpiperidine, and coumarin were not. Quercetin was equipotent with norharman as a monoamine oxidase A inhibitor and its metabolite, isorhamnetin, also inhibits. Total quercetin was the highest of the compounds in the sample diet. Although bioavailability was variable depending on the source, a healthy diet contains amounts of quercetin that might give sufficient amounts in brain to induce, by monoamine oxidase A inhibition, a small decrease in neurotransmitter breakdown.\n"}], "temperature": 0.0}}
{"custom_id": "R00038", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nOrganic-inorganic metal halides (OIMHs) have become a research hotspot in recent years due to their excellent luminescent properties and tunable emission wavelengths. However, the development of efficient red-light-emitting OIMHs remains a significant challenge. This work reports three Mn-based OIMHs derived from 1-methyl-1,2,3,4-tetrahydroisoquinoline hydrobromide: racemic one (Rac-TBM) and chiral ones (R-TBM and S-TBM). As a result of the synergism of chiral organic ligands inducing a unique lantern-shaped hybrid structure containing both tetrahedra and octahedra, Rac-TBM exhibits red-light emission with near-unity luminescence quantum yield. In comparison, the chiral counterparts R/S-TBM display strong green emission and circularly polarized luminescence (CPL) with a glum value up to +/- 2.5x10-2. Interestingly, a mixture of R- and S-TBM can transform into Rac-TBM, successfully achieving a sensitive and reversible switch between red light of octahedra and green light of tetrahedra under external stimuli. The outstanding luminescent properties allow Rac-TBM to be utilized not only for X-ray radioluminescence with a detection limit down to 46.29 nGys-1, but also for advanced information encryption systems to achieve leak-proof decryption.\n"}], "temperature": 0.0}}
{"custom_id": "R00039", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nIsoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine or 1-methyl-4-phenylpyridinium (MPP+) are potential endogenous neurotoxins causing nigral cell death from Parkinson's disease. We now report the effects of 7 days unilateral supranigral infusion in rats of four isoquinoline derivatives, namely N-n-propylisoquinolinium (N-Pr-IQ+), N-methyl-6,7-dimethoxyisoquinolinium (N-Me-6,7-diOMe-IQ+), 6,7-dimethoxy-1-styryl-3,4-dihydroisoquinoline (6,7-diOMe-1-S-3,4-DHIQ) and 1,2,3,4-tetrahydroisoquinoline (THIQ) compared to MPP+. MPP+ (33 nmol/24h)-infused rats showed a marked reduction in motor activity and displayed ipsilateral postural asymmetry. Administration of apomorphine or (+)-amphetamine to these animals produced robust contralateral and ipsilateral rotations, respectively. In contrast, rats infused with the isoquinoline derivatives (150 nmol/24h) did not show spontaneous or drug-induced motor changes. Infusion of MPP+ decreased the number of tyrosine hydroxylase (TH)-positive cells in the ipsilateral substantia nigra pars compacta (SNc) by approximately 90%. Infusion of N-Me-diOme-IQ+ and THIQ produced approximately 42% and 20% ipsilateral SNc cell loss, respectively, but N-Pr-IQ+ and 6,7-diOMe-1-S-3,4-DHIQ did not alter SNc cell numbers. MPP+ markedly depleted the dopamine (DA, 95%), 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) content of the ipsilateral striatum. N-Me-diOMe-IQ+ and THIQ also reduced the DA content of the ipsilateral striatum by approximately 39% and 20% respectively, but N-Pr-IQ+ and 6,7-diOme-1-S-3,4-DHIQ did not deplete striatal DA content. The isoquinoline derivatives slightly reduced (N-Me-diOMe-IQ+ and THIQ) or had no effect (N-Pr-IQ+ and 6,7-diOMe-1-S-3,4-DHIQ) on DOPAC or HVA levels. In conclusion, some isoquinoline derivatives that are substrates for the dopamine re-uptake system and inhibitors of mitochondrial function, are toxic to nigral dopaminergic neurones. Chronic exposure to endogenous or exogenous isoquinoline derivatives might contribute to cell death in Parkinson's disease.\n"}], "temperature": 0.0}}
{"custom_id": "R00040", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nThe molecular and functional diversity of G protein-coupled receptors is essential to many physiological processes. However, this diversity presents a significant challenge to understanding the G protein-mediated signaling events that underlie a specific physiological response. To increase our understanding of these processes, we sought to gain control of the timing and specificity of G(s) signaling in vivo. We used naturally occurring human mutations to develop two G(s)-coupled engineered receptors that respond solely to a synthetic ligand (RASSLs). Our G(s)-coupled RASSLs are based on the melanocortin-4 receptor, a centrally expressed receptor that plays an important role in the regulation of body weight. These RASSLs are not activated by the endogenous hormone alpha-melanocyte-stimulating hormone but respond potently to a selective synthetic ligand, tetrahydroisoquinoline. The RASSL variants reported here differ in their intrinsic basal activities, allowing the separation of the effects of basal signaling from ligand-mediated activation of the G(s) pathway in vivo. These RASSLs can be used to activate G(s) signaling in any tissue, but would be particularly useful for analyzing downstream events that mediate body weight regulation in mice. Our study also demonstrates the use of human genetic variation for protein engineering.\n"}], "temperature": 0.0}}
{"custom_id": "R00041", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nAims: 5-HT1A receptor antagonists constitute a potential group of drugs in the treatment of CNS diseases. The aim of this study was to search for new procognitive and antidepressant drugs among amide derivatives of aminoalkanoic acids with 5-HT1A receptor antagonistic properties. Materials & methods: Thirty-three amides were designed and evaluated in silico for their drug-likeness. The synthesized compounds were tested in vitro for their 5-HT1A receptor affinity and functional profile. Moreover, their selectivity over 5-HT7, 5-HT2A and D-2 receptors and ability to inhibit phosphodiesterases were evaluated. Results: A selected 5-HT1A receptor antagonist 20 (K-i = 35 nM, K-b = 4.9 nM) showed procognitive and antidepressant activity in vivo. Conclusion: Novel 5-HT1A receptor antagonists were discovered and shown as potential psychotropic drugs.\n"}], "temperature": 0.0}}
{"custom_id": "R00042", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nAn enantiomeric separation of dopamine-derived neurotoxins by capillary electrophoresis has been developed. Tetrahydroisoquinoline (TIQ), dopamine (DA), (R/S)-1-benzyl-TIQ (BTIQ), (R/S)-6,7-dihydroxy-1-methyl-TIQ (salsolinol, Sal), and (R/S)-6,7-dihydroxy-1, 2-dimethyl TIQ (N-methyl-salsolinol, NMSal) were studied as model compounds. The CE running buffer (50 mM phosphate buffer at pH 3.0) contained 1.5 M urea and 12 mM beta-CD as a chiral selector. During separation, the (R)-enantiomers formed more stable inclusion complexes with beta-CD, and thus had a longer migration time than their optical antipodes. It was noticed that the recovery rates of these TIQ derivatives were very poor (< 15%) during protein precipitation, a procedure widely used for cleaning up biological samples. The recovery was significantly improved by pre-mixing the sample with a surfactant (e.g., sodium hexanesulfonate or Triton X-100) to reduce the co-precipitation. The present method in combination with electrospray ionization tandem mass spectrometry (ESI-MS/MS) was applied to study samples obtained from in vitro incubation of two catecholamines, dopamine and epinine, with aldehydes forming neurotoxins including (S)- and (R)-NMSal enantiomers. The later is known to induce Parkinsonism in rats.\n"}], "temperature": 0.0}}
{"custom_id": "R00043", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nTwo benzyltetrahydroisoquinoline - protoberberine dimers, longiberine (1) and O-methyllongiberine (2), were isolated from the roots of Thalictrum longistylum and represent a new class of dimeric alkaloids. The structure of longiberine (1) was established by spectral and chemical methods. Reductive cleavage of O-ethyllongiberine (4) with Na/liquid NH3 yielded (+)-(S)-N-methylcoclaurine (5) which determined one-half of the dimer, and ID and 2D NMR studies arranged the substituents on the protoberberine nucleus. Chemical conversion of thalidezine (6) to 1 via the O-acetyl N,N-didemethyl derivative 9, which was methylenated in the Mannich reaction and N-methylated by the Eschweiler-Clarke procedure, established the second asymmetric center as S and confirmed the ring size and the order of the substituents for 1. Methylation of 1 with diazomethane formed the O-methyl derivative 2, identical with the natural product.\n"}], "temperature": 0.0}}
{"custom_id": "R00044", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nPeptides containing N-methylamino acids can exhibit improved pharmacodynamic and pharmacokinetic profiles compared to nonmethylated peptides, and therefore interest in these N-methylated peptides has been increasing in recent years. Arodyn (Ac[Phe(1,2,3),Arg(4),D-Ala(8)]Dyn A(1-11)NH2) is an acetylated dynorphin A (Dyn A) analog that is a potent and selective kappa opioid receptor antagonist (Bennett et al., J Med Chem 2002, 45, 5617), and its analog [NMePhe(1)]arodyn shows even higher affinity and selectivity for kappa opioid receptors (Bennett et al., I Pept Res 2005, 65, 322). During the synthesis of [NMePhe(1)]arodyn analogs, the arodyn(2-11) derivatives were obtained as major products. Analysis indicated that Ac-NMePhe was lost from the completed peptide sequence during acidic cleavage of the peptides from the resin and that the acetyl group played an important role in this side reaction. Different cleavage conditions were evaluated to minimize this side reaction and maximize the yield of pure [NMePhe(1)]arodyn analogs. Modifications to the N-terminus of the peptides to prevent the side reaction were also explored. The incorporation of a heteroatom-containing group such as methoxycarbonyl as the N-terminal functionality prevented this side reaction, while the incorporation of a bulky acyl group could not. Substituting NMePhe with the conformationally constrained analog Tic (1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid) also prevented the side reaction. (C) 2010 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 96: 97-102, 2011.\n"}], "temperature": 0.0}}
{"custom_id": "R00045", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nResults from previous investigations have suggested an important role for central epinephrine (EPI) systems in mediating the stimulatory effects of ovarian hormones on LH release in ovariectomized female rats. The purpose of these experiments was 1) to test whether selective inhibition of EPI synthesis blocks the sequential accumulation and decline of LHRH concentrations in the median eminence that precedes the ovarian hormone-induced LH surge and 2) to test whether the stimulatory ovarian hormone regimen enhances the activity of EPI systems in the hypothalamus. Ovariectomized rats were treated with estradiol, followed 2 days later by progesterone. Animals were treated before progesterone administration with saline, one of the EPI synthesis inhibitors [SK&F 64139 (2,3-dichloro-tetrahydroisoquinoline HCl) or LY 78335 (dichloro-alpha-methylbenzylamine)], or the dopamine-beta-hydroxylase inhibitor FLA-63 (bis-4-methyl-1-homopiperazinyl thiocarbonyl disulfide), which inhibits NE and EPI synthesis. The catecholamine synthesis inhibitors blocked or delayed the afternoon LH surge. FLA-63 completely prevented the accumulation of LHRH in the median eminence that preceded the rise in LH release. However, selective EPI synthesis inhibition with SK&F 64139 only partially prevented this increase in LHRH. A second EPI synthesis inhibitor, LY 78335, delayed both the LH surge and the rise in LHRH. In a second experiment, the administration of estradiol and progesterone to ovariectomized rats increased the alpha-methyltyrosine-induced depletion of hypothalamic EPI, suggesting increased activity in this system during the LH surge. Further experiments localized this effect to the medial basal hypothalamus. The depletion of both NE and EPI after synthesis inhibition was also enhanced during an earlier period, approximating the time of LHRH accumulation. These results suggest that the ovarian hormones activate both NE and EPI systems to stimulate the early afternoon rise of LHRH in the median eminence and to induce the subsequent LH surge.\n"}], "temperature": 0.0}}
{"custom_id": "R00046", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nA seven -step ex -chiral -pool synthesis of optically active 4alkylidenetetrahydroisoquinolines was developed. Starting from 6-bromopiperonal and (S)-serine S )-serine esters, N -benzylation via reductive amination gave enantiopure N -piperonyl serine esters. Subsequent NH and OH protection delivered defined (S)-serine S )-serine building blocks. The best results to achieve the conversion into the corresponding serinal were obtained via a two-step sequence of NaBH4/LiCl reduction and subsequent TEMPO oxidation. Then, chain elongation using the Masamune- Roush variant of the Horner olefination afforded ethyl (E)-4-(N-6-bro- E )-4-( N -6-bro- mopiperonyl)-substituted pentenoates in high yields. Intramolecular Heck cyclization employing the Herrmann-Beller catalyst enabled generation of enantiopure 4-(2-ethoxycarbonylmethylidene)tetrahydroisoquinoline building blocks in high Z -selectivity. Subsequent selected functional group transformations gave carbinols and lactones, which can be used as key intermediates in crinane alkaloid total syntheses.\n"}], "temperature": 0.0}}
{"custom_id": "R00047", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nThe effect of acetaldehyde on urinary salsolinol (6, 7-dihydroxy-l-methyl-1,2,3,4-tetrahydroisoquinoline) after ethanol intake was investigated. Healthy Japanese male volunteers were divided into two groups, i.e., a normal aldehyde dehydrogenase (ALDH) group of 13 subjects with a low Km isozyme of ALDH and a deficient group of 12 subjects. The subjects were given 0.4 or 0.8 g/kg of ethanol. Blood ethanol and acetaldehyde levels, urinary excretions of salsolinol, norepinephrine, epinephrine and dopamine were determined. A significant elevation of salsolinol in urine was found after intake of 0.8 g/kg of ethanol in the two groups, but the increase in the deficient group was greater than that in the normal group, while 0.4 g/kg of ethanol did not affect the excretion of salsolinol in either group. Blood acetaldehyde was highly correlated with urinary salsolinol (r = 0.88, p less than 0.001) and the correlation coefficient was greater than that between blood ethanol and salsolinol.\n"}], "temperature": 0.0}}
{"custom_id": "R00048", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nBackground: Most of the currently used antidepressant drugs are monoamine-based compounds, acting by the inhibition of re-uptake or metabolism of noradrenaline (NA) and/or serotonin (5-HT), because these neurotransmitters play a key role in the pathophysiology of depression. The aim of this study was to investigate the potential antidepressant-like activity of an endogenous amine, 1,2,3,4-tetrahydroiso quinoline (TIQ) and its close derivative, 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ).Methods: The experiments were carried out on male C57BL6J mice. The antidepressant-like activity of TIQs was evaluated in the behavioral tests: the forced swim test (FST) and tail suspension test (TST) and neurochemical analysis. TIQ and 1MeTIQ were administrated in three differences doses of 10, 25 or 50 mg/kg. Imipramine (IMI; 15 or 30 mg/kg) was used as a reference drug. In the neurochemical ex vivo study, the levels of NA, 5-HT and their metabolites, the rate of monoamine metabolism and their neuronal activity in different mouse brain structures were determined by HPLC with electrochemical detection.Results: The results of this study have demonstrated that TIQ and 1MeTIQ produced antidepressant-like effect in the FST and TST because they significantly decreased the immobility time comparably to IMI. Biochemical data have demonstrated that administration of TIQs led to the activation of NA and 5-HT systems.Conclusions: The results reported in this paper indicate that TIQ and 1MeTIQ possess a distinct antidepressant activity. In the light of these findings, we suggest that both tested compounds may be effective for the depression therapy in a clinical setting with better tolerance of side effects. (C) 2017 Published by Elsevier Sp. z o.o. on behalf of Institute of Pharmacology, Polish Academy of Sciences.\n"}], "temperature": 0.0}}
{"custom_id": "R00049", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nAppropriately substituted benzylamine (BZA) derivatives, fragmented derivatives of tetrahydroisoquinolines, were found to be directly acting adrenergic beta-stimulants, exhibiting tracheal relaxing, positive chronotropic and free fatty acid (FFA) releasing activities. The chemical structures essential for manifestation of the beta-action were i) 3,4-dihydroxybenzylamine, ii) arylmethyl group at position alpha, iii) lower alkyl group on the N atom. The structure activity relationships of BZA-derivatives were almost similar to, but partly different from those of tetrahydroisoquinoline- and catecholamine-derivatives. The tracheal relaxing, positive chronotropic and FFA-releasing actions of alpha-(3,4,5-trimethoxybenzyl)-N-methyl-3,4-dihydroxybenzylamine, the most active compound in the BZA-derivatives tested, were approximately one-hundred, thirty and fifty times less active than those of ISO, respectively. These results indicate that this compound is beta1-selective, while trimetoquinol is beta2-selective.\n"}], "temperature": 0.0}}
{"custom_id": "R00050", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nCovalent organic frameworks (COFs) have been considered as a family of attractive photocatalysts, which have shown unique advantages in photocatalytic applications. Multicomponent polycondensation strategy is growing as one of the most important methods for syntheses of functionalized COFs materials. Herein, under solvothermal conditions, four building blocks of 2-hydroxy-1,3,5-benzenetrialdehyde (HTB), 2,4,6-trihydroxy-1,3,5-benzenetrialdehyde (TTB), benzidine (BD), 3,3 '-dimethyl-[1,1 '-biphenyl]-4,4 '-diamine (DMBZ) were selected to synthesize ketoenamine-linked framework material DBTH4-COF with high crystallinity and stability. The resultant COF has a suitable optical band gap, strong photocurrent response and low impedance, indicative of high potential for heterogeneous photocatalysis. After evaluation, DBTH4-COF exhibited the preminent photocatalytic performance in photosynthesis of benzimidazoles. Cycling experiments also showed high stability and recyclability of the DBTH4-COF. The high-performance DBTH4-COF was further employed as a heterogeneous catalyst for photocatalytic oxidative of amines to imines and oxidation of tetrahydroisoquinoline to dihydroisoquinolone. Some control experiments were performed to gain further insights into the nature of photocatalysis. The current research also provided a valuable approach for developing COFs catalysts to meet challenges in photocatalytic organic transformations.\n"}], "temperature": 0.0}}
{"custom_id": "R00051", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nA series of novel dinuclear platinum(II) complexes with (1S, 3S)-1,2,3,4-tetrahydroisoquinolines as the ligands were synthesized as potential anticancer agents in several steps starting from commercially available L-DOPA. The cytotoxicities of the series of dinuclear platinum(II) complexes of tetrahydroisoquinoline were tested against HCT-8, BEL-7402, A2780, MCF-7, Hela, A549 and BGC-823 cell lines by the MTT test. These complexes showed selective inhibition activity against cisplatin-insensitive cell line Skov3. (C) 2013 Zhan-Zhu Liu. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved.\n"}], "temperature": 0.0}}
{"custom_id": "R00052", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nThree structurally closely related dopamine D1 receptor positive allosteric modulators (D1 PAMs) based on a tetrahydroisoquinoline (THIQ) scaffold were profiled for their CYP3A4 induction potentials. It was found that the length of the linker at the C5 position greatly affected the potentials of these D1 PAMs as CYP3A4 inducers, and the level of induction correlated well with the activation of the pregnane X receptor (PXR). Based on the published PXR X-ray crystal structures, we built a binding model specifically for these THIQ-scaffold-based D1 PAMs in the PXR ligand-binding pocket via an ensemble docking approach and found the model could explain the observed CYP induction disparity. Combined with our previously reported D1 receptor homology model, which identified the C5 position as pointing toward the solvent-exposed space, our PXR-binding model coincidentally suggested that structural modifications at the C5 position could productively modulate the CYP induction potential while maintaining the D1 PAM potency of these THIQ-based PAMs.\n"}], "temperature": 0.0}}
{"custom_id": "R00053", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nThe design, synthesis and pharmacological evaluation of a novel class of Dmt-Tic dipeptide analogues are described. These resulting analogues bearing different C-terminal functionalities were found to bind to the human delta receptor with high affinity. One specific class of dipeptides bearing urea/thiourea functionalities showed partial to full activation of the delta receptor. Several dipeptides also showed good binding affinities with full activation of the human kappa receptor, a novel property for those ligands.\n"}], "temperature": 0.0}}
{"custom_id": "R00054", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nAn I2-DMSO mediated multicomponent [3+2] cascade annulation reaction using methyl ketones, 1,2,3,4tetrahydroisoquinolines (THIQ) and cyclopropenones as readily available substrates has been developed. This metal-free process involves N-H/alpha-C(sp3)-H trifunctionalization of THIQ and C- C bond cleavage of cyclopropenone, providing a direct approach to obtain pyrrolo[2,1-a]isoquinoline derivatives with a quaternary carbon center. Two C-C bonds and one C-N bond are formed efficiently in one pot.\n"}], "temperature": 0.0}}
{"custom_id": "R00055", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nAs one of marine tetrahydroisoquinoline alkaloids, renieramycin T plays a significant role in inhibiting tumor metastasis and invasion. However, the effect of renieramycin T on inflammation-related tumor metastasis and invasion is still unknown, and its mechanisms remain unclear. Here we established an inflammation-related tumor model by using the supernatant of RAW264.7 cells to simulate B16F10 mouse melanoma cells. The results indicate that renieramycin T suppressed RAW264.7 cell supernatant-reduced B16F10 cell adhesion to a fibronectin-coated substrate, migration, and invasion through the matrigel in a concentration-dependent manner. Moreover, Western blot results reveal that renieramycin T attenuated the phosphorylation of STAT3 and down-regulated the expression of Nrf2. Together, the above findings suggest a model of renieramycin T in suppressing B16F10 cancer cell migration and invasion. It may serve as a promising drug for the treatment of cancer metastasis.\n"}], "temperature": 0.0}}
{"custom_id": "R00056", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nXenobiotic enzymic systems have been studied in Parkinson's disease. Platelet monoamine oxidase-B activity is increased by the use of phenylethylamine but decreased by the use of dopamine as substrate. Enzymes involved with sulfur oxidation and methylation are underactive.\n"}], "temperature": 0.0}}
{"custom_id": "R00057", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nA facile method for the synthesis of N-aryl-substituted azacycles from arylamines and cyclic ethers has been developed. In this study, arylamines were treated with cyclic ethers in the presence of POCI3 and DBU to provide five- and six-membered azacycles. Using this method, various azacycloalkanes, isoindolines, and tetrahydroisoquinolines were prepared in high yields. This synthetic method offers an efficient approach to the production of azacycles from cyclic ethers.\n"}], "temperature": 0.0}}
{"custom_id": "R00058", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\n[GRAPHICS]An efficient and straightforward synthesis of isoquinolines is reported from internal alkenyl boronic esters, easily prepared from the corresponding 1,2-bis(boronates), via a sequential copper-catalyzed azidation/aza-Wittig condensation. This synthetic method has been used to synthesize quinisocaine, a topical anesthetic used for the treatment of pain and pruritus, and further extended to thieno[2,3-c]pyridines by using 2-thiophenecarboxaldehyde as coupling partner in the first step.\n"}], "temperature": 0.0}}
{"custom_id": "R00059", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nThe question of whether hydrogen atom transfer (HAT) or electron transfer (ET) is the key step in the activation of N-aryl tetrahydroisoquinolines in oxidative coupling reactions using CuBr as catalyst and tert-butyl hydroperoxide (tBuOOH) has been investigated. Strong indications for a HAT mechanism were derived by using different para-substituted N-aryl tetrahydroisoquinolines, showing that electronic effects play a minor role in the reaction. Hammett plots of the Cu-catalyzed reaction, a direct time-resolved kinetic study with in situ generated cumyloxyl radicals, as well as density functional calculations gave essentially the same results. We conclude from these results and from kinetic isotope effect experiments that HAT is mostly mediated by tert-butoxyl radicals and only to a lesser extent by tert-butylperoxyl radicals, in contrast to common assumptions. However, reaction conditions affect the competition between these two pathways, which can significantly change the magnitude of kinetic isotope effects.\n"}], "temperature": 0.0}}
{"custom_id": "R00060", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nApoptosis is a form of call death that is manifested in Parkinson's disease (PD) and certain other neurodegenerative disorders. Metabolites of salsolinol (SAL), an intraneuronal, dopamine-derived tetrahydroisoquinoline (TIQ), have been shown to induce apoptosis in human dopaminergic neuroblastoma cells, implicating these molecules as causative or contributory factors in the selective killing of nigrostriatal dopaminergic neurons, a cardinal manifestation of Parkinson's disease. Since insects employ dopamine and related catecholamines in a variety of processes including cuticular sclerotization and cellular immune reactions, it was of interest to know how insect cells metabolized exogenous SAL. Propidium iodide staining combined with flow cytometry showed that IPLB-LdFB cells from Lymantria dispar exhibited no significant (P < 0.05) increase in apoptosis when incubated for 48 h with concentrations of SAL ranging from 10 mu M to 1 mM. A significant increase in apoptosis (P < 0.05) was observed in cell cultures containing the highest concentration of SAL tested (5 mM), but only 12.4% of the cells manifested this form of cell death. High pressure liquid chromatography with electrochemical detection (HPLC-ED) was used to document the production of two potentially cytotoxic quinonoids generated during the outoxidation of SAL, a reaction that was found to be significantly (P < 0.05) enhanced by peroxidose. The resistance of IPLB-LdFB cells to SAL-induced apoptosis is attributed to the ability of these insect calls to metabolize and/or detoxify such dopamine-derived catecholic TIQs. Thus, the biochemical pathways employed by insect cells in these processes may be of considerable interest to individuals investigating certain neurodegenerative disorders. Arch. Insect Biochem. Physiol. 49:1-9, 2002. (C) 2002 Wiley-Liss, Inc.\n"}], "temperature": 0.0}}
{"custom_id": "R00061", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nTwo new bis(monoterpenoid) indole alkaloid glucosides, bahienoside A (1) and bahienoside B (2), together with five known compounds, 5alpha-carboxystrictosidine, angustine, strictosamide, and (E)- and (Z)-vallesiachotamine, were isolated from the aerial parts of Psychotria bahiensis collected in Trinidad, West Indies. The structures of the compounds were elucidated using 1D and 2D NMR spectral methods, viz., H-1, C-13, C-13 DEPT, H-1-H-1 COSY, HSQC, HMQC, HMBC, and TOCSY aided by IR, UV, and circular dichroism measurements.\n"}], "temperature": 0.0}}
{"custom_id": "R00062", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nAsymmetric alkynylation of seven-membered cyclic imine dibenzo[b,f][1,4]oxazepines is successfully achieved by combining chiral phosphoric acid and Ag(I) catalysts. Various arylacetylenes, conjugated enynes, and terminal 1,3-diynes are good substrates for this reaction, and aliphatic hexyne is also a suitable donor at elevated temperature. Optimization of this approach has provided a facile method to synthesize optically active 11-substituted-10,11-dihydrodibenzo[b,f][1,4]oxazepine derivatives containing a carbon-carbon triple bond with 63-99% ee. Subsequent transformations of the carbon-carbon triple bond for the heterocyclic products have been disclosed.\n"}], "temperature": 0.0}}
{"custom_id": "R00063", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nThis work details an asymmetric gold-ligand cooperative catalysis that transforms readily accessible chiral/achiral propargylic sulfonamides into chiral 3-pyrrolines. A bifunctional biphenyl-2-ylphosphine ligand featuring a chiral tetrahy-droisoquinoline fragment is essential for the observed metal-ligand cooperation and the asymmetric induction. 2,5-cis-3-Pyrrolines are formed with excellent diastereoselectivities in a matched scenario. The mismatched scenario by using the ligand enantiomer delivers 2,5-trans-3-pyrrolines with >5/1 diastereoselectivity. The synthetic utilities of this chemistry are demonstrated.\n"}], "temperature": 0.0}}
{"custom_id": "R00064", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nPhenotypic screening of an annotated small molecule library identified the quinuclidine tetrahydroisoquinoline solifenacin (1) as a robust enhancer of progranulin secretion with single digit micromolar potency in a murine microglial (BV-2) cell line. Subsequent SAR development led to the identification of 29 with a 38-fold decrease in muscarinic receptor antagonist activity and a 10-fold improvement in BV-2 potency.\n"}], "temperature": 0.0}}
{"custom_id": "R00065", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nA seven-step enantioselective total synthesis of (-)-terengganensine A, a complex heptacyclic monoterpene indole alkaloid, was accomplished. Key steps included: a) Noyori's catalytic enantioselective transfer hydrogenation of the iminium salt to set up the absolute configuration at the C21 position; b) a highly diastereoselective C7 benzoyloxylation with dibenzoyl peroxide under mild conditions; and c) an integrated one-pot oxidative cleavage of cyclopentene/triple cyclization/hydrolysis sequence for the construction of the dioxa azaadamantane motif with complete control of four newly generated stereocenters.\n"}], "temperature": 0.0}}
{"custom_id": "R00066", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nA chemoenzymatic strategy for the synthesis of enantiomerically pure novel alkaloids (1S,3R)-1-benzyl-2,3-dimethyl-1,2,3,4-tetrahydroisoquinolines is presented. The key steps are the biocatalytic stereoselective reductive amination of substituted 1-phenylpropan-2-one derivatives to yield chiral amines employing microbial omega-transaminases, and the diastereoselective reduction of a Bischler-Napieralski imine intermediate by catalytic hydrogenation in the presence of palladium on charcoal, leading exclusively to the desired cis-isomer. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.\n"}], "temperature": 0.0}}
{"custom_id": "R00067", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nHigh stereoselectivities were found in a wide range of superacid-catalyzed Pictet-Spengler cyclization reactions. Particularly in the cases of 2-alkyl-N-benzylidene-2-phenethylamines, an enhanced stereoselectivity was observed under the superacid conditions as compared with the corresponding weak acid (TFA)-catalyzed (monocationic) cyclization reaction of the N-benzylidene-2-(3',4'-dimethoxy)phenethylamines that bear electron-donating groups on the cyclizing aromatic ring. The computational study also supported the energetic favorability of the cyclization of the N,N-diprotonated imine and revealed a significantly early transition-state structure.\n"}], "temperature": 0.0}}
{"custom_id": "R00068", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nA non-specific N-methyltransferase was demonstrated in dog liver. This enzyme is different from other N-methylating systems, especially in terms of substrate and species specificity. The enzyme catalyzes the methylation of a variety of endogenous and exogenous amines; of the compounds studied, SK&F 64139 (7,8-dichloro-1,2,3,4-tetrahydroisoquinoline) was found to be the best substrate. The enzyme utilized S-adenosylmethionine but not 5-methyltetrahydrofolate as a methyl donor, and it had a pH optimum at 8.0. Study of SK&F 64139 with the partially purified enzyme indicated that this dog liver N-methyltransferase had very low Km and high Vmax values for SK&F 64139. Methylation of SK&F 64139 was not observed with the monkey or rat liver enzyme preparation. This finding is in accordance with the fact that SK&F 64139 is methylated extensively in the dog, but not in other species. The ability of this enzyme to methylate a number of arylalkylamines suggests its possible importance in drug biotransformation.\n"}], "temperature": 0.0}}
{"custom_id": "R00069", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nC-3-functionalized tetrahydroisoquinolines (THIQs) structural motifs are found in numerous natural products such as the tetrahydroprotoberberine alkaloids (coralydine and corytenchirine) and the benzophenanthridine alkaloids (homochelidonine, norchelidonine and chelamine). These scaffolds are also highly valuable compounds in drug discovery. Therefore, in the past few years, there has been a growing interest in developing new methods for the synthesis of this building block. However, unlike C-1-functionalized tetrahydroisoquinolines which are easily accessible, construction of C-3-functionalized tetrahydroisoquinolines is highly challenging. Methodologies such as the Bischler-Napieralski cyclization/reduction sequence, radical cyclization approach, and palladium-catalysed aryl-aryl coupling/reduction reactions were mostly used. However, all of these methods require multi step synthesis and prefunctionalization of the substrate. Moreover, none of these strategies are of sufficiently general applicability, especially for the synthesis of tetrahydro-3,4'-biisoquinoline. Herein, we have successfully developed an unprecedented cascade approach under mild conditions to access complex C-3-functionalized tetrahydroisoquinolines. The keystone of the present cascade process is the successive formation of two iminium intermediates resulting to the formation of 3 new bonds, therefore allowing creation of molecular complexity and diversity starting from simple substrates.\n"}], "temperature": 0.0}}
{"custom_id": "R00070", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nThe development of efficient electrocatalysts for nitrite reduction to ammonia, especially integrated with a value-added anodic reaction, is important. Herein, Ni nanosheet arrays with Ni vacancies (Ni-NSA-V-Ni) were demonstrated to exhibit outstanding electrocatalytic performances toward selective nitrite reduction to ammonia (faradaic efficiency: 88.9%; selectivity: 77.2%) and semi-dehydrogenation of tetrahydroisoquinolines (faradaic efficiency: 95.5%; selectivity: 98.0%). The origin and quantitative analyses of ammonia were performed by N-15 isotope labeling and H-1 NMR experiments. The decrease in electronic cloud density induced by the Ni vacancies was found to improve the NO2- adsorption and NH3 desorption, leading to high nitrite-to-ammonia performance. In situ Raman results revealed the formation of Ni-II/Ni-III active species for anodic semi-dehydrogenation of tetrahydroisoquinolines on Ni-NSA-V-Ni. Importantly, a Ni-NSA-V-Ni||Ni-NSA-V-Ni bifunctional two-electrode electrolyzer was constructed to simultaneously produce ammonia and dihydroisoquinoline with robust stability and high selectivity.\n"}], "temperature": 0.0}}
{"custom_id": "R00071", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nIn the title compound, C18H16N4, the dihedral angle between the benzene and phenyl rings is 61.40 (4)°. In the crystal, mol-ecules are linked by N-H⋯N(nitrile) hydrogen bonds, forming inversion dimers. The dimers are further linked by N-H⋯N(amine) hydrogen bonds, and both units are arranged almost perpendicular to each other [angle between dimer mean planes = 84.43 (12)°]. This arrangement is extended to form a ladder-like structure parallel to the c axis.\n"}], "temperature": 0.0}}
{"custom_id": "R00072", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nThe development of an intermolecular aza-Diels-Alder (DA) cycloaddition of sultines and imines is reported. By exploiting sultines as o-quinodimethane precursors and aryl imines as dienophiles in the presence of Cu(OTf)(2), an aza-DA reaction proceeds to provide a wide variety of 3-aryl tetrahydroisoquionlines in moderate to excellent yield (up to 89%). The synthetic utility of these products was demonstrated in the preparation of tetracyclic N-heterocycles, including a tetrahydroprotoberberine skeleton.\n"}], "temperature": 0.0}}
{"custom_id": "R00073", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nThe synergy of a solution-phase preparation of scaffolds with a solid-phase combinatorial synthesis let to develop an efficient route to a small library of chiral, highly functionalized tetrahydroisoquinolines. Both loading on the Merrifield resin and the key acid-catalyzed Pictet-Spengler condensation were efficiently promoted by microwave irradiation. The library was designed such that up to five points of diversity would be potentially introduced, making the strategy in principle suitable for generation of a large number of compounds.\n"}], "temperature": 0.0}}
{"custom_id": "R00074", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nTwo new push-pull molecules with imidazole-4,5-dicarbonitrile acceptor, thiophene and 2-methoxythiophene donors with potential use in photoredox catalysis were designed and prepared. The synthesis started from commercially available imidazole-4,5-dicarbonitrile and its bromination and N-methylation. Subsequent Suzuki-Miyaura cross-coupling with (5-methoxy)thiophene-derived boronic acids afforded target push-pull derivatives. Beside common analytical methods, the molecular structure of 5-methoxythiophen-2-yl derivative has also been verified by X-ray analysis. DSC analyses showed remarkable thermal stabilities of both target derivatives with T-m and T-D values above 150 and 270 degrees C, respectively. Fundamental properties and extent of the intramolecular charge-transfer were further studied by UV-VIS absorption spectra and DFT calculations. Fundamental photoredox properties of target imidazole derivatives were elucidated. Both push-pull molecules were preliminary tested as photoredox catalysts in cross-dehydrogenative coupling reaction between tetrahydroisoquinoline and nitromethane and the results were compared with those obtained by pyrazine2,3-dicarbonitrile-derived catalyst.[GRAPHICS]\n"}], "temperature": 0.0}}
{"custom_id": "R00075", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nDearomatization of two-dimensional (2D) planar aromatic feedstocks enables the introduction of three-dimensional (3D) vectors to new molecular scaffolds, vastly expanding the chemical space for drug discovery. Here, we demonstrate that photoinduced single-electron reduction of quinolines under polysulfide anion photocatalysis triggers dearomative dimerization and an unprecedented skeletal rearrangement. In the presence of excess formate as the stoichiometric reductant, a complex polyheterocyclic hybrid of a 2,5-methanobenzo[b]azepine and a tetrahydroisoquinoline is formed in a net-reductive manner, whereas in the presence of a trialkylamine instead of formate, sequential dimerization and skeletal rearrangement occurs to afford 4-(3-indolylmethyl)quinolines in a redox-neutral manner. The remarkable way in which the additive dictates the reaction course showcases the unique tunability of polysulfide anion mediated redox photocatalysis. These observations enabled the design of a net-reductive skeletal rearrangement of 4-arylquinolines to 3-(arylmethyl)indoles. Detailed mechanistic investigations reveal that this umpolung transformation from electron-deficient quinolines to electron-rich indoles is mediated via a 1,2-aryl migration/ring-contraction sequence, as opposed to the more commonly invoked neophyl-like rearrangement. [GRAPHICS]\n"}], "temperature": 0.0}}
{"custom_id": "R00076", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nThe antioxidant activity of Psychotria carthagenensis, P. leiocarpa, P. capillacea and P. deflexa (Rubiaceae) extracts were investigated, and the concentrations of total phenolics, flavonoids, condensed tannins and flavonols were determined. The chemical compositions of the extracts were investigated using the high performance liquid chromatography (HPLC/PAD) method. We used 1,1-diphenyl-1-picrylhydrazyl free radical (DPPH), beta-Carotene bleaching and 2,2-azinobis (3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) radical cations to determine antioxidant activity. The ability to scavenge radical was measured in these experiments by the discoloration of the solution. Concentrations of constituents were measured spectrophotometrically. P. carthagenensis and P. capillacea exhibited the highest antioxidant activity, in the DPPH test, beta-carotene bleaching and ABTS system. The highest phenolic, flavonoid, condensed tannin and flavonol concentration was found in P. carthagenensis and P. capillacea extracts. HPLC-PDA analysis of P. carthagenensis and P. capillacea revealed hydroxycinnamic acid (p-coumaric acid). This is the first report on the antioxidant properties and constituent analysis of these Psychotria extracts.\n"}], "temperature": 0.0}}
{"custom_id": "R00077", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nSaframycin A (SFM-A), a tetrahydroisoquinoline antibiotic isolated from Streptomyces lavendulae, shows potent anti-proliferation activities against a variety of tumor cell lines, and shares the core structure with ecteinascidin 743 (ET-743), the anticancer drug for soft-tissue sarcoma. Characterization of the SFM-A biosynthetic gene cluster revealed three nonribosomal peptide synthetase genes and a series of genes encoding oxygenases. To investigate the function of sfmO2 gene, encoding a FAD-dependent monooxygenase/hydroxylase, we constructed the gene replacement mutant (Delta sfmO2) strain S. lavendulae TL2007 and the corresponding gene complementation mutant strain S. lavendulae TL2008. A novel compound, SFM-O, was isolated from the Delta sfmO2 replacement mutant strain and its structure was characterized by comparison to the HRMS and NMR spectra of SFM-A. These findings indicated that SfmO2 is responsible for the oxidation of ring A in the biosynthetic pathway of SFM-A, and the new compound SFM-O could be considered as an advanced intermediate in the semisynthesis of ET-743.\n"}], "temperature": 0.0}}
{"custom_id": "R00078", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nTransition-metal-catalyzed direct carbon-hydrogen bond functionalization has made significant advances in the field of carbon-hydrogen bond activation over the past decades. This methodology has the potential to be used in many different areas of chemistry; for example, it can provide an opportunity for the synthesis of various kinds of complex compounds. This account mainly focuses on recent advances in transition-metal-catalyzed direct sp(3)-carbon-hydrogen bond functionalization to form carbon-carbon bonds. 1 Introduction 2 Carbon-Carbon Bond Formation via Direct sp(3)-Carbon-Hydrogen Bond Functionalization 2.1 Coupling of sp(3)-Carbon-Hydrogen and sp-Carbon-Hydrogen Bonds 2.2 Coupling of sp(3)-Carbon-Hydrogen and sp(2)-Carbon-Hydrogen Bonds 2.3 Coupling of sp(3)-Carbon-Hydrogen and sp(3)-Carbon-Hydrogen Bonds 2.4 Coupling of sp(3)-Carbon-Hydrogen and C-X Bonds 3 Conclusion\n"}], "temperature": 0.0}}
{"custom_id": "R00079", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nAporphine compounds constitute a class of substances with important pharmacological properties, including anticancer, antiviral, anti-HIV, anti-inflammatory, and leishmanicidal activities. Consequently, several strategies to obtain the aporphine core have been reported. Herein this review, we provide an overview of two relevant approaches used to construct the C-ring in the synthetic routes developed. The first approach, which is based on a one-bond disconnection, allows C-ring formation using a 1-benzyl-1,2,3,4-tetrahydroisoquinoline intermediate (mainly) employing cyclization reactions catalyzed by metals or promoted by light. The second approach, which is derived from a two-bond disconnection, leads to C-ring formation via a sequence of reactions starting with [4+2] cycloadditions. Through these approaches, aporphinoids with a diverse range of substitution patterns and biological activities can be synthesized.\n"}], "temperature": 0.0}}
{"custom_id": "R00080", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nThe asymmetric total synthesis of (-)-saframycin A, a natural antitumor product of the tetrahydroisoquinoline antitumor antibiotics family, has been accomplished by employing L-tyrosine as the starting chiral building block in 24 steps for the longest linear sequence in an overall yield of 9.7%. The key steps in the synthesis involve stereoselective intermolecular and intramolecular Pictet-Spengler reactions, which induced the correct stereochemistry at C-1 and C-11, respectively. The selective protection-deprotection protocol of an amino group in the two-step transformation from intermediate 10 to 12 and a hydroxyl group in the first two steps resulted in both high selectivity and efficiency of the synthetic route.\n"}], "temperature": 0.0}}
{"custom_id": "R00081", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nA novel, practical, and efficient synthesis of (-)-N-{2-[(R)-3-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide monophosphate (YM758 monophosphate, (R)-1 center dot H3PO4 (Figure 1) is described. The target molecule (R)-1 has a potent If current channel inhibitor. Medicinal chemistry synthetic routes were very long and suffered from extensive use of chlorinated solvents and silica-gel column chromatography. A number of steps in the medicinal chemistry route were also unattractive for large-scale synthesis due to some reasons for example the use of unstable intermediates. An important objective of a new synthetic route was avoidance of such a use of unstable intermediate, and it was achieved by the discovery of an important 4,5-dihydrooxazole intermediate 19 and ring-opening N-alkylation of chiral amine with 19 under acidic condition. The new procedure does not require any purification by column chromatography for all steps. The overall yield was significantly improved from 14% or 34% to 49% compared to that of the medicinal synthetic routes. This highly efficient process was successfully demonstrated at a pilot-scale operation, yielding 36.5 kg of (R)-1 center dot H3PO4.\n"}], "temperature": 0.0}}
{"custom_id": "R00082", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\n(1SR,4RS)-3,3-Dimethyl-1,2,3,4-tetrahydro-1,4-(epiminomethano)naphthalenes were synthesized in 2-3 steps from commercially available materials and assessed for specificity and effectiveness across a range of Nox isoforms. The N-pentyl and N-methylenethiophene substituted analogs 11g and 11h emerged as selective Nox2 inhibitors with cellular IC50 values of 20 and 32 mu M, respectively.\n"}], "temperature": 0.0}}
{"custom_id": "R00083", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nIt has been recently observed that salsolinol (1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline), a putative endogenous prolactin-releasing factor is a potent inhibitor of stress-induced release of epinephrine and norepinephrine. The prolactin release caused by salsolinol was inhibited by 1-methyl-3,4-dihydroisoquinoline (1MeDIQ). Therefore, the aim of our present studies was to investigate the effect of 1MeDIQ on plasma catecholamine levels. It has been found that 1MeDIQ is able to induce a massive increase in plasma catecholamine levels. Pretreatment of the animals with a ganglionic blocker, chlorisondamine, could completely abolish the effect of 1MeDIQ on plasma norepinephrine, and plasma epinephrine levels were only significantly attenuated. Spinal cord transection between cervical and thoracic segments eliminated 1MeDIQ induced increase in epinephrine, whereas increase in plasma norepinephrine was not affected. Hence, this effect of 1MeDIQ on sympathoadrenal system activity is most probably mediated through the level of sympathetic ganglia or partially at more centrally located sites of the nervous system. These results suggest that elevation of plasma catecholamines is involved in the mechanism of action of 1MeDIQ inhibiting the biological effect of salsolinol. (C) 2004 Elsevier B.V. All rights reserved.\n"}], "temperature": 0.0}}
{"custom_id": "R00084", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nProtein arginine methyltransferases 5 (PRMT5) is a clinically promising epigenetic target that is upregulated in a variety of tumors. Currently, there are several PRMT5 inhibitors under preclinical or clinical development, however the established clinical inhibitors show favorable toxicity. Thus, it remains an unmet need to discover novel and structurally diverse PRMT5 inhibitors with characterized therapeutic utility. Herein, a series of tetrahydroisoquinoline (THIQ) derivatives were designed and synthesized as PRMT5 inhibitors using GSK-3326595 as the lead compound. Among them, compound 20 (IC50: 4.2 nM) exhibits more potent PRMT5 inhibitory activity than GSK-3326595 (IC50: 9.2 nM). In addition, compound 20 shows high anti-proliferative effects on MV-4-11 and MDA-MB-468 tumor cells and low cytotoxicity on AML-12 hepatocytes. Furthermore, compound 20 possesses acceptable pharmacokinetic profiles and displays considerable in vivo antitumor efficacy in a MV-4-11 xenograft model. Taken together, compound 20 is an antitumor compound worthy of further study.\n"}], "temperature": 0.0}}
{"custom_id": "R00085", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nMany anticancer drugs are ineffective in tumors that have functional DNA repair mechanisms. In contrast, trabectedin, a tetrahydroisoquinoline alkaloid marine natural product, stands out as it is more lethal to cancer cells with active DNA repair, particularly transcription-coupled nucleotide excision repair (TC-NER), making it an intriguing alternative to standard chemotherapeutic agents. To optimize trabectedin's use in precision oncology, it is essential to understand how its toxicity depends on TC-NER. In this study, we reveal that incomplete TC-NER of trabectedin-DNA adducts generates persistent single-strand breaks (SSBs). These adducts are found to obstruct the second of two sequential NER-mediated DNA incisions. By mapping the 3'-hydroxyl groups of SSBs resulting from the first NER incision at trabectedin-DNA adducts, we achieve genome-wide visualization of TC-NER. Our findings show that trabectedin-induced SSBs predominantly occur in the transcribed strands of active genes, accumulating near transcription start sites. This work provides new insights into how trabectedin can be leveraged for targeted cancer therapies and for studying TC-NER and transcription.\n"}], "temperature": 0.0}}
{"custom_id": "R00086", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nTrabectedin is a tetrahydroisoquinoline molecule that binds to the N2 of guanine in the minor groove, causing DNA damage and affecting transcription regulation in a promoter- and gene-specific manner. The antitumor activity of trabectedin appears to be not only related to its direct effects on cancer cells, but also on the tumor microenvironment. In cancer cells, the drug induces cell cycle arrest and cell death that is not dependent on p53 status, and it is increased dramatically in cells deficient in homologous recombination (e.g., cells with mutations of BRCA1/2). Trabectedin also has potent immunomodulatory effects, being selectively cytotoxic against monocytes and tumor-associated macrophages. In addition, it inhibits production of proinflammatory and angiogenic mediators, which induces changes in the tumor microenvironment and contributes to its antitumor activity. The opportunity to combine direct cytotoxic activity with a capacity to favorably modify the tumor microenvironment, using either single-agent or combination therapy, is an especially appealing therapeutic option for a diverse range of cancers.\n"}], "temperature": 0.0}}
{"custom_id": "R00087", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nAn ab initio calculation of the title molecule was performed to interpret previously observed electronic spectra of the title system. Since the computation concerns the isolated molecule, possible effects of solvent molecules had to be taken into account, especially for such as Rydberg states. The S-3 <- S-0, S-2 <- S-0, and S-1 <- S-0 absorption bands are (re)assigned to the excited states of the L-b, L-a/CT, and n(N)sigma* (3s) states, respectively. The minor S-1(a) <- S-0 absorption observed at the red area of the S-1(n) <- S-0 band in acetonitrile is reinterpreted as being a n(N)pi* (CT) state. Correspondingly, the pi, nN, and aN fluorescence spectra are (re)ascribed to the excited states of the L-b, n(N)sigma*, and n(N)pi* states, respectively. The n(N)sigma* and n(N)pi* states are found to be restricted to the equatorial and axial conformers, respectively. The exceptionally long progression of the pi fluorescence in hexane is interpreted as being due to the closeness of the L, and L-b states.\n"}], "temperature": 0.0}}
{"custom_id": "R00088", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\n1,2,3,4-tetrahydro-2-methyl-4,6,7-isoquinolinetriol (TMIQ), a tetrahydroisoquinoline derivative of adrenaline, was tested for potency as an analog of the dopamine depleting agent 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in assays of tyrosine hydroxylase (TH) activity in the striatal synaptosome preparation. TMIQ inhibited TH activity with an IC50 (4 x 10(-6)M) similar to that found for MPTP (IC50 1 x 10(-6)M). TH inhibitions produced by IC50 concentrations of TMIQ were reversed by monoamine oxidase (MAO)-A or MAO-B inhibitors (clorgyline or deprenyl), or the dopamine reuptake blocker nomifensine, or excess cofactor (6R)-5,6,7,8-tetrahydro-L-biopterin. TMIQ did not appear to act at the presynaptic D2 sulpiride sensitive autoreceptor for dopamine synthesis modulation. These in vitro data are consistent with earlier findings that TMIQ acts as a dopamine depleting agent, and with the possibility that TMIQ may have a degree of MPTP-like activity in vivo.\n"}], "temperature": 0.0}}
{"custom_id": "R00089", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nThe enzyme phenylethanolamine N-methyltransferase (PNMT, EC 2.1.1.28) catalyzes the final step in the biosynthesis of epinephrine and is a potential drug target, primarily for the control of hypertension. Unfortunately, many potent PNMT inhibitors also possess significant affinity for the a(2)-adrenoceptor, which complicates the interpretation of their pharmacology. A bisubstrate analogue approach offers the potential for development of highly selective inhibitors of PNMT. This paper documents the design, synthesis, and evaluation of such analogues, several of which were found to possess human PNMT (hPNMT) inhibitory potency <5 nM versus AdoMet. Site-directed mutagenesis studies were consistent with bisubstrate binding. Two of these compounds (19 and 29) were co-crystallized with hPNMT and the resulting structures revealed both compounds bound as predicted, simultaneously occupying both substrate binding domains. This bisubstrate inhibitor approach has resulted in one of the most potent (20) and selective (vs the a(2)-adrenoceptor) inhibitors of hPNMT yet reported.\n"}], "temperature": 0.0}}
{"custom_id": "R00090", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\n1. A series of substituted tetrahydroisoquinolins derived from the cleavage products of tetrandrine were found to inhibit [3H]-nitrendipine binding to rat cerebral cortical membranes. Those compounds which displaced [3H]-nitrendipine binding were also able to inhibit high KCl-induced contraction of rat aorta in vitro. 2. There was a significant correlation between the ability of these tetrahydroisoquinolines to inhibit [3H]-nitrendipine binding and KCl-induced contraction (r = 0.99, P less than 0.001). 3. CPU-23 (1-(1-[(6-methoxy)-naphth-2-yl])-propyl-2-(1-piperidine)-acetyl- 6,7- dimethoxy-1,2,3,4-tetrahydroisoquinoline), one of the most potent compounds identified in this series, behaved as a simple competitive inhibitor at the [3H]-nitrendipine binding site and reduced the apparent affinity but not the maximal number of binding sites in saturation analysis. 4. In contrast to nifedipine which caused hypotension and tachycardia, CPU-23 induced both hypotension and bradycardia in a dose-dependent manner in pentobarbitone-anaesthetized Sprague-Dawley rats, spontaneously hypertensive and age-matched normotensive WKY rats. 5. It is suggested that CPU-23 may exert its cardiovascular effects via interaction with the dihydropyridine binding site on the L-type calcium channel.\n"}], "temperature": 0.0}}
{"custom_id": "R00091", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nAn efficient diastereoselective route is developed to get access to novel spiropyrrolo[1,2-a]isoquinoline-oxindole skeletons by a one-pot three-component [3 + 2] cycloaddition reaction of (Z)-5-arylidene-1,3-thiazolidine-2,4-diones, isatin derivatives, and 1,2,3,4-tetrahydroisoquinoline (THIQ). Interestingly, the regioselectivity of the reaction is both temperature-and solvent-dependent, allowing the synthesis of two regioisomeric endo-dispiropyrrolo[2,1-a]isoquinolineoxindoles in excellent yield. Unprecedentedly, each isomeric dispiropyrrolo[2,1-a]isoquinolineoxindole endured retro-1,3-dipolar cycloaddition/recycloaddition reactions under thermal or catalytic conditions to regenerate the corresponding regioisomeric counterpart. In addition, DFT calculations were performed at the M062X/6-31++g(d,p) level of theory to unravel the origin of the reversal of regioselectivity and endo-stereoselectivity of the title 1,3-dipolar cycloaddition reactions. Upon treatment of Isatin, THIQ with (Z)-4-arylidene-5-thioxo-thiazolidin-2-ones as dipolarophiles, unusual rhodanine analogues were formed, along with smaller amounts of a dispirooxindole-piperazine. The structure and the relative configuration of these N-heterocycles were unambiguously assigned by spectroscopic techniques and confirmed by four single-crystal structures. In vitro and in vivo studies reveal that the novel rhodanine derivatives exert antidiabetic activity. The binding affinity with the active site of the enzyme a-amylase was studied by molecular docking. Furthermore, the bioavailability assessed through virtual ADME parameters (Absorption, Distribution, Metabolism, Elimination pharmacokinetics) and the excellent fit with the Lipinski and Veber rules predict good drug-likeness properties for a bromo-substituted 2-sulfanylidene-1,3-thiazolidin-4-one.\n"}], "temperature": 0.0}}
{"custom_id": "R00092", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nCytochrome P450 (CYP) 2D6 is an enzyme that is expressed in liver and brain. It can inactivate neurotoxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 1,2,3,4-tetrahydroisoquinoline and beta-carbolines. Genetically slow CYP2D6 metabolizers are at higher risk for developing Parkinson's disease, a risk that increases with exposure to pesticides. The goal of this study was to investigate the neuroprotective role of CYP2D6 in an in-vitro neurotoxicity model. SH-SY5Y human neuroblastoma cells express CYP2D6 as determined by western blotting, immunocytochemistry and enzymatic activity. CYP2D6 metabolized 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin and the CYP2D6-specific inhibitor quinidine (1 mu m) blocked 96 +/- 1% of this metabolism, indicating that CYP2D6 is functional in this cell line. Treatment of cells with CYP2D6 inhibitors (quinidine, propanolol, metoprolol or timolol) at varying concentrations significantly increased the neurotoxicity caused by 1-methyl-4-phenylpyridinium (MPP+) at 10 and 25 mu m by between 9 +/- 1 and 22 +/- 5% (P < 0.01). We found that CYP3A is also expressed in SH-SY5Y cells and inhibiting CYP3A with ketoconazole significantly increased the cell death caused by 10 and 25 mu m of MPP+ by between 8 +/- 1 and 30 +/- 3% (P < 0.001). Inhibiting both CYP2D6 and CYP3A showed an additive effect on MPP+ neurotoxicity. These data further support a possible role for CYP2D6 in neuroprotection from Parkinson's disease-causing neurotoxins, especially in the human brain where expression of CYP2D6 is high in some regions (e.g. substantia nigra).\n"}], "temperature": 0.0}}
{"custom_id": "R00093", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nThis work reports on the trypanocidal activity of a series of symmetric triruthenium complexes combined with azanaphthalene ligands of general formula [Ru3O(CH3COO)(6)(L)(3)]PF6 (L = (1) quinazoline (qui), (2) 5-nitroisoquinoline (5-nitroiq), (3) 5-bromoisoquinoline (5-briq), (4) isoquinoline (iq), (5) 5-aminoisoquinoline (5-amiq), and (6) 5,6,7,8-tetrahydroisoquinoline (thiq)). All complexes within the series presented in vitro trypanocidal activity against both the trypomastigote and amastigote forms of T. cruzi. The IC50 values obtained for complexes 1-6 ranged from 1.39 to 165.9 mu M for the trypomastigote form and from 1.06 to 53.16 mu M for the amastigote form. These values were lower than the values observed for the metallic core [Ru3O (CH3COO)(6)(CH3OH)(3)](+) itself and for the free ligands in all cases. Remarkably, complex 6 displayed lower IC50 values than the reference drug (benznidazole) for the acute (trypomastigote form) and chronic (amastigote form) phases of Chagas disease. These findings, combined with the low toxicity against healthy cells (LLK-MK2 strain) and a high SI value (Selectivity Index > 10) make complex 6 an excellent candidate for in vivo tests.\n"}], "temperature": 0.0}}
{"custom_id": "R00094", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nDerivatives of peptides of the TIPP (Tyr-Tic-Phe-Phe; Tic = 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid) family containing a guanidino (Guan) function in place of the N-terminal amino group were synthesized in an effort to improve their blood-brain barrier permeability. Unexpectedly, N-terminal amidination significantly altered the in vitro opioid activity profiles. Guan-analogues of TIPP-related delta opioid antagonists showed delta partial agonist or mixed delta partial agonist/mu partial agonist activity. Guanidinylation of the mixed mu agonist/delta antagonists H-Dmt-Tic-Phe-Phe-NH2 (DIPP-NH2) and H-Dmt-Tic Psi[CH2NH]Phe-Phe-NH2 (DIPP-NH2[Psi]) converted them to mixed mu agonist/delta agonists. A docking study revealed distinct positioning of DIPP-NH2 and Guan-DIPP-NH2 in the delta receptor binding site. Lys(3)-analogues of DIPP-NH2 and DIPP-NH2[Psi] (guanidinylated or non-guanidinylated) turned out to be mixed mu/kappa agonists with delta antagonist-, delta partial agonist- or delta full agonist activity. Compounds with some of the observed mixed opioid activity profiles have therapeutic potential as analgesics with reduced side effects or for treatment of cocaine addiction. (C) 2013 Elsevier Ltd. All rights reserved.\n"}], "temperature": 0.0}}
{"custom_id": "R00095", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nUsing a microdialysis-HPLC technique in conscious rats, we examined the action of (R)-1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, (R)-salsolinol (R-Sal), a possible endogenous metabolite of alcohol, on serotonin (5-HT) and dopamine (DA) metabolism in four regions of the brain: the striatum, the substantia nigra, the hippocampus and the hypothalamus. Following 1 mM R-Sal perfusion, the dialysate level of 5-HT in the striatum markedly increased from non-detectable levels to 4259.2 +/- 617.5 nM, while DA increased from 3.4 +/- 0.9 nM to 206.0 +/- 56.5 nM. This increase was one order of magnitude larger in 5-HT than in DA. Conversely, the output of 5-hydroxyindoleacetic acid decreased markedly to non-detectable levels, while 3,4-dihydroxyphenylacetic acid and homovanillic acid outputs decreased below 40% of basal levels. These effects were dose-related to R-Sal (1 microM to 1 mM) and were confirmed also in 3 other brain regions. The R-Sal-induced responses in the striatum were observed even after pretreatment of 2 microM tetrodotoxin, a blocker of nerve-firing activity, via the dialysis membrane. The repetitive perfusion with 1 mM R-Sal into the striatum induced the reproducible response of 5-HT and DA. Furthermore, the potencies of 1 mM R-Sal to increase the output of 5-HT and DA were approximately 783.0-fold and 2.6-fold stronger, respectively, than those of the same dose of methamphetamine. The results suggest that R-Sal acts to stimulate a release of monoamines, 5-HT preferentially, with inhibition of monoamine oxidase and catechol-O-methyltransferase activities.\n"}], "temperature": 0.0}}
{"custom_id": "R00096", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nThe chemically exfoliated 2D-MoS2 has a mixture of 1T (metallic) and 2H (semiconducting) phases. It has shown a considerably good catalytic activity for hydrogen evolution reaction (HER), proceeding via electrochemical as well as photochemical pathways. Experimentalists have utilized triethanolamine or other sacrificial donors along with Eosin Y as a photosensitizer. But the potential of this reaction has not yet been fully explored as the sacrificial donor is wasted in the oxidation process. The oxidation cycle of this process can be used in many organic transformation(s). Herein, we report the use of the oxidative cycle for efficient cross dehydrogenative coupling (CDC) reaction with tetrahydroisoquinoline and indole substrates as well as their derivatives, parallel to HER. The reaction results in good to excellent yield of the corresponding product under visible light irradiation at room temperature. The mechanistic investigation has also been carried out. This study is a potential example of how to fully harness the oxidation and reduction cycles of many semiconductor based photocatalysts.\n"}], "temperature": 0.0}}
{"custom_id": "R00097", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nTetrandrine (Tet) is a macrocyclic tetrahydroisoquinoline alkaloid isolated from Stephania tetrandra S. Moore along with other Chinese and Japanese herbs. It has been used extensively for the treatment of silicosis, autoimmune disorders, inflammatory diseases and cardiovascular diseases. Of late, Tet has garnered increasing attention for its anticancer activity and its efficacy to reverse chemoresistance. In this study, we evaluated the cytotoxicity of Tet on MGC 803 gastric cancer cells using the methyl thiazolyl tetrazolium (MTT) assay. In addition, apoptosis and cell cycle were analyzed through flow cytometry, mitochondrial membrane potential (MMP) was measured using fluorescence microscopy and migration of cells was determined by transwell assay. It was observed that Tet efficiently inhibited the proliferation of MGC 803 cells in a concentration-dependent and time-dependent manner and reduced the number of colonies at low concentrations. It induced apoptosis through mitochondrial dysfunction, which may be related with upregulated Bcl-2-associated X protein (Bax), and downregulated of B cell lymphoma 2 (Bcl-2). On the other hand, Tet blocked the cell cycle at Gap 2 (G2)/mitosis (M) phase, which was associated with the upregulation of p21(CIP1/WAF1). Furthermore, Tet elevated the intracellular reactive oxygen species (ROS) level and suppressed the migration of MGC 803 cells. Altogether, we demonstrated that Tet inhibited the proliferation and migration of gastric cancer MGC 803 cells and thus might be a potential drug candidate for the treatment of gastric cancer.\n"}], "temperature": 0.0}}
{"custom_id": "R00098", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\n1. From the urine of rats, rabbits and humans treated with noscapine, two novel metabolites were isolated and identified as 7-hydroxy-6-methoxyphthalide (MA-1) and 6-hydroxy-7-methoxyphthalide (MA-2), mainly by mass spectrometry. 2. MA-2 (free and conjugated) amounted to 8.5% dose in rats (n=2) and 1.7% dose in rabbits (n=2) during the first 48 h. In humans, MA-2 was excreted in amounts of 6.0 to 10.3% dose in the first 24 h urine (three men and a woman), although one woman excreted 52.5% dose as MA-2 during the same period. In all three species MA-2 was excreted 10 times more as conjugates than as the free metabolite. MA-1 was excreted only in trace amounts in the urines of three species. 3. In rabbits, the drug was metabolized also to 1-alpha-methyl-8-methoxy-6,7-dihydroxy-1-(6,7-dimethoxy-3-phthalidyl)-1,2,3,4-tetrahydroisoquinoline (4.6% dose, conjugated only) using g.l.c.-mass spectrometry. This metabolite was excreted conjugated at 0.6 to 5.2% dose in five human subjects, but was not detected in rats. 4. Three 0-demethylated metabolites of noscapine, previously reported, were determined using g.l.c.-mass spectrometry. The total demethylated metabolites (free and conjugated) amounted to 0.2%, 4.0% and 0.1-1.5% dose, respectively, in rats, rabbits and humans (n=5) in the first 24 h urine.\n"}], "temperature": 0.0}}
{"custom_id": "R00099", "body": {"messages": [{"role": "system", "content": "您作为四氢异喹啉类生物碱的研究专家，您需要根据文献的摘要，锁定关键信息，并输出指定JSON格式结果。"}, {"role": "user", "content": "\n    请严格遵循以下规则分析这篇摘要：\n（注意：回答必须使用JSON格式，严格按照下面的输出格式输出，无额外解释。若文献未提及相关内容，字段值应为 `null`）\n\n# 判断逻辑\n1. ​**四氢异喹啉类生物碱判定**​（需同时满足）：\n   - 明确提及化合物属于\"四氢异喹啉类生物碱\"（tetrahydroisoquinoline alkaloids）或具体亚类（如苄基异喹啉类）\n   - 排除以下干扰项：\n     - 单纯提及四氢异喹啉类（无生物碱结构）\n     - 非四氢异喹啉类生物碱\n     - 模糊表述（如\"可能含有生物碱\"）\n\n2. ​**研究方向判定**​（若`has_tetrahydroisoquinoline_alkaloids`为true）：\n   - ​**结构鉴定**​：需包含\"分离(isolation)\"和\"结构鉴定(structure elucidation)\"等证据\n   - ​**活性研究**​：需提供具体靶点名称及实验数据（如IC50）\n   - ​**生物合成**​：需明确前体、产物、关键酶的三要素\n\n# 输出规则\n1. 字段层级关系：\n   - `compounds`数组中每个对象必须包含`classification`字段，取值示例：\n     - benzylisoquinoline alkaloids（苄基异喹啉生物碱）\n     - 1-benzylisoquinolines alkaloids（1-苄基异喹啉）\n     - bisbenzylisoquinolines alkaloids（双苄基异喹啉）\n     - morphinans alkaloids（吗啡烷）\n     - aporphines alkaloids（阿朴啡）\n     - protoberberines alkaloids（原小檗碱）\n     - phthalideisoquinolines alkaloids（苯并菲啶）\n     - benzophenanthridines alkaloids（苯酞异喹啉）\n     - protopines alkaloids（原阿片）\n     - pavines alkaloids\n     - phenethylisoquinoline alkaloids（苯乙基异喹啉生物碱）\n     - Amaryllidaceae alkaloids（石蒜科生物碱）\n     - ipecac alkaloids（吐根生物碱）\n   - 每个化合物的生物活性(`bioactivity`)和物种来源(`species`)独立关联\n   - 未被文献明确提及的字段必须设为 `null`\n\n2. 数据提取规范：\n   - 分类名称：必须使用英文术语（如benzylisoquinoline alkaloids）\n   - 化合物名称：优先使用文献中的命名（如Plumulane A）\n   - 物种拉丁名：必须使用斜体格式（如 _\"Fissistigma polyanthum\"_）\n   - 靶点名称：精确到分子级别（如AChE 而非\"抗氧化活性\"）\n\n# 输出格式（严格按照这个格式输出）\n{\n  \"has_tetrahydroisoquinoline_alkaloids\": true,\n  \"research_type\": [\"structure\", \"activity\", \"biosynthesis\"],\n  \"compounds\": [\n    {\n      \"name\": \"Plumulane A\",\n      \"classification\": \"benzylisoquinoline alkaloids\",\n      \"species\": {\n        \"source\": [\"_Fissistigma polyanthum_\"], \n        \"part_used\": \"roots\"\n      },\n      \"bioactivity\": [\n        {\n          \"target\": \"EGFR kinase\",\n          \"mechanism\": \"competitive inhibition\",\n          \"value\": \"IC50 = 2.3 μM\",\n          \"cell_line\": \"HepG2\"\n        }\n      ]\n    }\n  ],\n  \"biosynthesis\": {\n    \"routes\": [\n      {\n        \"substrate\": \"geranylgeranyl diphosphate\",\n        \"product\": \"pendulumine A\",\n        \"key_enzymes\": [\"CYP719A21\"],\n        \"evidence\": [\"isotope labeling\"]\n      }\n    ]\n  }\n}\n\n# 待分析摘要：\nThe endogenous neurotoxin, 1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (salsolinol), has been considered a potential neurotoxin in the etiology of Parkinson's disease (PD). Salsolinol and N-methyl(R)-salsolinol were identified in the brains and cerebrospinal fluid (CSF) of PD patients. Oxidative stress is known to be one of the major contributing factors in the cascade that may finally leads to the cell death in PD. The present study was undertaken to understand the role of salsolinol in oxidative-mediated neuronal toxicity in dopaminergic SH-SY5Y cells, and the neuroprotective effects of metallothionein (MT) against salsolinol toxicity in MT overexpressing (MTtrans) fetal mesencephalic cells. Salsolinol increased the production of reactive oxygen species (ROS) and significantly decreased glutathione (GSH) levels and cell viability in SH-SY5Y cells. Salsolinol also decreased intracellular ATP levels and induced nuclear condensation in these cells. Salsolinol-induced depletion in cell viability was completely prevented by N-acetylcysteine in SH-SY5Y cells, and also prevented by MT in MTtrans fetal mesencephalic cells compared to control(wt) cells. The extent of nuclear condensation and caspase activation was also less in MTtrans cells than control(wt) cells. These results suggest that salsolinol causes oxidative stress by decreasing the levels of GSH and by increasing ROS production, and these events may lead to the death of dopaminergic cell. Furthermore, MT overexpression may protect dopaminergic neurons against salsolinol-induced neurotoxicity, most probably by the inhibition of oxidative stress and apoptotic pathways including caspase-3 activation. (C) 2004 Elsevier B.V All rights reserved.\n"}], "temperature": 0.0}}
